{
    "schema": "uplifting.world/list/v1",
    "licence": {
        "name": "CC BY 4.0",
        "url": "https://creativecommons.org/licenses/by/4.0/",
        "attribution": "Uplifting World — Medicamentos para emagrecer",
        "terms": "Reutilização livre, inclusive comercial, com atribuição e uma ligação para a página de origem."
    },
    "theme": {
        "slug": "weight-loss-drugs",
        "status": "live",
        "name": "Medicamentos para emagrecer",
        "standfirst": "O que está aprovado, onde, e o que os ensaios mostraram de facto — mais um retrato honesto do que se vende online sem qualquer evidência por trás.",
        "url": "https://uplifting.world/pt-pt/weight-loss-drugs",
        "locale": "pt-pt",
        "cadence_days": 14,
        "last_verified_at": "2026-08-20T00:00:00+00:00",
        "next_review_at": "2026-09-03T00:00:00+00:00",
        "generated_at": "2026-08-21T11:22:37+00:00"
    },
    "counts": {
        "entities": 33,
        "retired": 6,
        "core_cells": {
            "total": 198,
            "absent": 79,
            "published": 119,
            "percent": 40
        },
        "changes": 412
    },
    "fields": [
        {
            "key": "brand",
            "label": "Marca",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": null
        },
        {
            "key": "drug_class",
            "label": "Classe",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": null
        },
        {
            "key": "route",
            "label": "Via de administração",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": null
        },
        {
            "key": "dose",
            "label": "Dose",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": null
        },
        {
            "key": "weight_change",
            "label": "Variação de peso",
            "type": "number",
            "unit": "%",
            "decimals": 1,
            "is_core": true,
            "help": "Variação média do peso corporal com o medicamento no seu próprio ensaio pivotal. Não é comparável entre ensaios sem o braço de placebo ao lado."
        },
        {
            "key": "placebo_change",
            "label": "Braço de placebo",
            "type": "number",
            "unit": "%",
            "decimals": 1,
            "is_core": true,
            "help": null
        },
        {
            "key": "placebo_adjusted",
            "label": "Ajustado ao placebo",
            "type": "number",
            "unit": "pp",
            "decimals": 1,
            "is_core": true,
            "help": "O braço do medicamento menos o seu próprio braço de placebo, em pontos percentuais. É a única figura desta página que pode ir num só eixo — e mesmo assim os ensaios são diferentes."
        },
        {
            "key": "trial",
            "label": "Ensaio pivotal",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": true,
            "help": null
        },
        {
            "key": "trial_n",
            "label": "Participantes",
            "type": "number",
            "unit": null,
            "decimals": 0,
            "is_core": true,
            "help": null
        },
        {
            "key": "trial_weeks",
            "label": "Duração",
            "type": "number",
            "unit": "weeks",
            "decimals": 0,
            "is_core": true,
            "help": null
        },
        {
            "key": "discontinuation",
            "label": "Abandono por efeitos adversos",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": null
        },
        {
            "key": "human_rct",
            "label": "Evidência humana aleatorizada",
            "type": "text",
            "unit": null,
            "decimals": 0,
            "is_core": false,
            "help": "O resultado de uma pesquisa no ClinicalTrials.gov e na PubMed, não uma suposição. «Nenhuma» é um resultado de pesquisa com data."
        }
    ],
    "agencies": {
        "fda": {
            "name": "FDA",
            "jurisdiction": "United States",
            "full": "Food and Drug Administration",
            "lang": "en"
        },
        "ema": {
            "name": "EMA",
            "jurisdiction": "European Union",
            "full": "European Medicines Agency",
            "lang": "en"
        },
        "mhra": {
            "name": "MHRA",
            "jurisdiction": "United Kingdom",
            "full": "Medicines and Healthcare products Regulatory Agency",
            "lang": "en"
        },
        "anvisa": {
            "name": "ANVISA",
            "jurisdiction": "Brazil",
            "full": "Agência Nacional de Vigilância Sanitária",
            "lang": "pt"
        },
        "pmda": {
            "name": "PMDA",
            "jurisdiction": "Japan",
            "full": "Pharmaceuticals and Medical Devices Agency",
            "lang": "en"
        },
        "nmpa": {
            "name": "NMPA",
            "jurisdiction": "China",
            "full": "National Medical Products Administration",
            "lang": "en"
        },
        "hc": {
            "name": "Canada",
            "jurisdiction": "Canada",
            "full": "Health Canada",
            "lang": "en"
        },
        "tga": {
            "name": "TGA",
            "jurisdiction": "Australia",
            "full": "Therapeutic Goods Administration",
            "lang": "en"
        }
    },
    "entities": [
        {
            "slug": "semaglutide-24",
            "name": "Semaglutide 2.4 mg",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "The only weight-loss medicine with proven cardiovascular outcome benefit · First generic anywhere arrived in Canada through an administrative accident",
            "note": "Resultados clínicos — SELECT (N=17,604, mean 40 months) showed a real cardiovascular benefit in people with established heart disease and no diabetes: major adverse cardiac events 6.5% vs 8.0%, HR 0.80. This is the strongest outcome evidence for any medicine on this page.\n\nAdvertência em caixa — Thyroid C-cell tumours (rodent finding). Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.\n\nEfeitos adversos — Nausea 44%, diarrhoea 30%, vomiting 24%, constipation 24%. Serious: pancreatitis, gallbladder disease, acute kidney injury, pulmonary aspiration under anaesthesia.\n\nGenéricos — First generics for weight management have arrived, but not in the US. Health Canada authorised Apotex's Sevmia on 29 Jun 2026 — the first generic semaglutide indicated for chronic weight management, though other generic semaglutide products were already listed in Canada. Trade reporting attributes the early entry to a lapsed patent maintenance fee; Health Canada does not say so. Brazil approved locally-made generics (EMS, Germed) on 17 Aug 2026.\n\nPreço — US list $1,349.02 per 28-day package; manufacturer cash-pay $299/month. Covered under the Medicare GLP-1 Bridge from 1 Jul 2026 at roughly $50 to the beneficiary. No verifiable EU or Brazilian list price exists in a primary source.\n\nFornecimento — Shortage resolved 21 Feb 2025.",
            "unveiled_on": "2021-06-04",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Wegovy",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, weekly",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "2.4 mg weekly after a 16-week escalation",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -14.9,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2021;384:989",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.4,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2021;384:989",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -12.5,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2021;384:989",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "STEP 1",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2021;384:989",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 1961,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 68,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SELECT trial summary, NEJM 2023;389:2221",
                        "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                        "publisher": "acc.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2023-11-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "6.8% vs 3.2% placebo",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2021-06-04",
                    "date_precision": "day",
                    "indication_official": "NDA 215256. Four indications on the 03/2026 label, including cardiovascular risk reduction (Mar 2024) and non-cirrhotic MASH with F2–F3 fibrosis under accelerated approval (Aug 2025).",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy label, rev. 03/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2022-01-06",
                    "date_precision": "day",
                    "indication_official": "BMI ≥30, or ≥27 with a weight-related comorbidity. Adolescents from 12 years.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Wegovy EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2023-11-01",
                    "date_precision": "month",
                    "indication_official": "NICE restricts NHS use to tier 3/4 specialist services, maximum two years.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "approved",
                    "decided_on": "2023-01-01",
                    "date_precision": "month",
                    "indication_official": "Month-level date only; ANVISA does not publish an accessible day-level record.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "approved",
                    "decided_on": "2023-03-10",
                    "date_precision": "day",
                    "indication_official": "Narrower than the West: requires BMI ≥27 with two or more obesity-related disorders, or BMI ≥35. Sources give the decision date variously as 27 Mar and 10 Apr 2023.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "approved",
                    "decided_on": "2024-06-01",
                    "date_precision": "month",
                    "indication_official": "Month-level date only.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": "2021-11-25",
                    "date_precision": "day",
                    "indication_official": "BMI ≥30, or ≥27 with one comorbidity.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "Health Canada — first generic semaglutide approved",
                        "url": "https://www.canada.ca/en/health-canada/news/2026/06/canada-approves-first-generic-semaglutide-for-weight-loss.html",
                        "publisher": "Health Canada",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-06-29",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "tga",
                    "state": "approved",
                    "decided_on": "2024-01-01",
                    "date_precision": "month",
                    "indication_official": "Registered; specific decision date not retrievable. Not PBS-subsidised.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "semaglutide-72",
            "name": "Semaglutide 7.2 mg",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Almost every press account quotes −20.7% without the comparison arm; the registry has had it all along",
            "note": "Resultados clínicos — None specific to this dose.\n\nAdvertência em caixa — Thyroid C-cell tumours, as for 2.4 mg.\n\nEfeitos adversos — Same profile as 2.4 mg; dose-specific incidence not published.\n\nGenéricos — None.\n\nPreço — US manufacturer cash-pay $399/month for new patients.\n\nFornecimento — No shortage reported.",
            "unveiled_on": "2026-03-19",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Wegovy HD",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, weekly",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "7.2 mg weekly, escalated from 2.4 mg",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -19.5,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "registry-posted results, 7.2 mg · NCT05646706; Lancet Diab Endocrinol 2025 (PMID 40961952)",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -3.8,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "registry-posted results, 7.2 mg · NCT05646706; Lancet Diab Endocrinol 2025 (PMID 40961952)",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -15.7,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "registry-posted results, 7.2 mg · NCT05646706; Lancet Diab Endocrinol 2025 (PMID 40961952)",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "STEP UP",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "registry-posted results, 7.2 mg · NCT05646706; Lancet Diab Endocrinol 2025 (PMID 40961952)",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A dimensão da amostra do ensaio não foi divulgada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:32+00:00"
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 72,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                        "url": "https://clinicaltrials.gov/study/NCT05646706",
                        "publisher": "ClinicalTrials.gov NCT05646706",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado para esta dose",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:32+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2026-03-19",
                    "date_precision": "day",
                    "indication_official": "Weight reduction only — this dose does not carry the cardiovascular indication.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2026-07-15",
                    "date_precision": "day",
                    "indication_official": "European Commission approval of the single-dose pen; CHMP positive opinion 12 Dec 2025.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2026-01-01",
                    "date_precision": "month",
                    "indication_official": "BMI ≥30. Explicitly not licensed for cardiovascular risk reduction. NICE appraisal pending.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "oral-semaglutide",
            "name": "Semaglutide 25 mg, oral",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": "Tablet",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Removes the “there is no pill” argument that drove much grey-market buying",
            "note": "Resultados clínicos — The cardiovascular labelling rests on SOUL, which studied oral semaglutide 14 mg — the diabetes product, not this 25 mg obesity product. No dedicated outcome trial of the 25 mg dose exists.\n\nAdvertência em caixa — Thyroid C-cell tumours.\n\nEfeitos adversos — Gastrointestinal adverse events in 74% vs 42% placebo.\n\nGenéricos — None.\n\nPreço — US manufacturer cash-pay $149/month — the cheapest branded GLP-1 in the United States.\n\nFornecimento — No shortage reported.",
            "unveiled_on": "2025-12-22",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Wegovy tablets",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Tablet, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "25 mg daily, on an empty stomach with ≤120 ml water, then nothing for 30 minutes",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -14,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2025;393:1077",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2025;393:1077",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -12,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2025;393:1077",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "OASIS 4",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "treatment policy · NEJM 2025;393:1077",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 307,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 64,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "OASIS 4 — PubMed 40934115",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                        "publisher": "OASIS 4",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "7% vs 6% placebo",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2025-12-22",
                    "date_precision": "day",
                    "indication_official": "NDA 218316. Carries both weight reduction and cardiovascular risk reduction indications.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Wegovy tablets label, rev. 12/2025",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2025-12-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2026-07-15",
                    "date_precision": "day",
                    "indication_official": "First oral GLP-1 for weight management in the EU.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2026-06-11",
                    "date_precision": "day",
                    "indication_official": "First weight-loss tablet licensed in the UK.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "Pharmaceutical Journal — MHRA approves oral semaglutide",
                        "url": "https://pharmaceutical-journal.com/article/news/mhra-approves-semaglutide-oral-tablets-for-weight-loss",
                        "publisher": "Pharmaceutical Journal",
                        "kind": "trade",
                        "primary": false,
                        "published_on": "2026-06-11",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "anvisa",
                    "state": "review",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Submetido e em avaliação.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "tirzepatide",
            "name": "Tirzepatide",
            "maker": "Eli Lilly",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Largest weight effect of any approved medicine · Its cardiovascular evidence is weaker than semaglutide's, which is the reverse of the popular impression",
            "note": "Resultados clínicos — SURPASS-CVOT compared tirzepatide against active dulaglutide, not placebo: non-inferior, superiority not met. SURMOUNT-MMO, the obesity outcomes trial, is still running with no results. Anyone citing SURMOUNT-MMO results today is citing nothing.\n\nAdvertência em caixa — Thyroid C-cell tumours (rat finding).\n\nEfeitos adversos — Nausea 28%, diarrhoea 23%, constipation 17%, vomiting 13%, hair loss 5%.\n\nGenéricos — None anywhere. Composition-of-matter patents run into the mid-2030s.\n\nPreço — US self-pay $299–$449/month depending on dose. Only the Zepbound KwikPen is on the Medicare covered list.\n\nFornecimento — Shortage resolved 19 Dec 2024.",
            "unveiled_on": "2023-11-08",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Zepbound (US) / Mounjaro",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Dual GIP + GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, weekly",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "5, 10 or 15 mg weekly",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -20.9,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment regimen, 15 mg · NEJM 2022;387:205",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -3.1,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment regimen, 15 mg · NEJM 2022;387:205",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -17.8,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "treatment regimen, 15 mg · NEJM 2022;387:205",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "SURMOUNT-1",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "treatment regimen, 15 mg · NEJM 2022;387:205",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 2539,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 72,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SURMOUNT-1 — PubMed 35658024",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                        "publisher": "SURMOUNT-1",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2022-06-04",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "4.8–6.7% vs 3.4% placebo",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2023-11-08",
                    "date_precision": "day",
                    "indication_official": "NDA 217806. Obstructive sleep apnoea indication added 20 Dec 2024. No US cardiovascular indication.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Zepbound label, rev. 01/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2022-09-15",
                    "date_precision": "day",
                    "indication_official": "Weight management sits on the Mounjaro label; “Zepbound” is not an EU brand. No EU sleep apnoea indication.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2023-11-01",
                    "date_precision": "month",
                    "indication_official": "NICE phased NHS rollout from Dec 2024, starting at BMI ≥35 with comorbidity, over as long as twelve years.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "approved",
                    "decided_on": "2025-06-09",
                    "date_precision": "day",
                    "indication_official": "Weight-management indication; BMI >30, or >27 with comorbidities.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "Agência Brasil — ANVISA approves Mounjaro for weight loss",
                        "url": "https://agenciabrasil.ebc.com.br/saude/noticia/2025-06/anvisa-aprova-uso-do-medicamento-mounjaro-para-perda-de-peso",
                        "publisher": "Agência Brasil",
                        "kind": "trade",
                        "primary": false,
                        "published_on": "2025-06-09",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "pmda",
                    "state": "approved",
                    "decided_on": "2024-12-01",
                    "date_precision": "month",
                    "indication_official": "Approved for obesity; exact MHLW date not retrievable.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "approved",
                    "decided_on": "2024-07-19",
                    "date_precision": "day",
                    "indication_official": "Brand 穆峰达. Company announcement; NMPA document not retrieved.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": "2025-05-13",
                    "date_precision": "day",
                    "indication_official": "Zepbound KwikPen; launched 9 Jul 2025.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "approved",
                    "decided_on": "2023-01-01",
                    "date_precision": "month",
                    "indication_official": "Mounjaro registered with the weight-management indication. Zepbound is not registered in Australia. Not PBS-listed for obesity.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "orforglipron",
            "name": "Orforglipron",
            "maker": "Eli Lilly",
            "country": null,
            "region": null,
            "form": "Tablet",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "First small-molecule oral GLP-1 — no peptide manufacturing constraint, which is what makes global scale plausible · Approved in exactly one country",
            "note": "Resultados clínicos — None. No cardiovascular outcomes trial has reported.\n\nAdvertência em caixa — Thyroid C-cell tumours — applied as a class warning even though the label states orforglipron itself produced no tumours in rodents, because human relevance is undetermined.\n\nEfeitos adversos — At the top dose: nausea 35%, diarrhoea 25%, vomiting 24%, constipation 24%.\n\nGenéricos — None. New chemical entity.\n\nPreço — US self-pay from $149/month; Medicare Part D $50/month from 1 Jul 2026.\n\nFornecimento — No shortage reported.",
            "unveiled_on": "2026-04-01",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Foundayo",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Small-molecule (non-peptide) GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Tablet, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "Up to 17.2 mg daily, no food or water restrictions",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -11.1,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy, 17.2 mg · FDA label, Trial 1",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.1,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy, 17.2 mg · FDA label, Trial 1",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -9,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "treatment policy, 17.2 mg · FDA label, Trial 1",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "ATTAIN-1",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "treatment policy, 17.2 mg · FDA label, Trial 1",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 3127,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 72,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "8% vs 3% placebo — the highest of the GLP-1 agents",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2026-04-01",
                    "date_precision": "month",
                    "indication_official": "NDA 220934. Reviewed under the Commissioner's National Priority Voucher programme — approved 50 days after filing, 294 days ahead of its target date.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Foundayo label, rev. 04/2026",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-04-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "liraglutide",
            "name": "Liraglutide 3.0 mg",
            "maker": "Novo Nordisk; Teva (generic)",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "The first GLP-1 to face real generic competition — a preview of where the class goes",
            "note": "Resultados clínicos — LEADER showed cardiovascular benefit at the 1.8 mg diabetes dose. There is no outcome trial at the 3.0 mg obesity dose.\n\nAdvertência em caixa — Thyroid C-cell tumours.\n\nEfeitos adversos — Nausea 40%, diarrhoea 21%, vomiting 16%.\n\nGenéricos — The only genericised GLP-1. Teva launched generic liraglutide in the US on 28 Aug 2025.\n\nPreço — Brand reference around $1,324/month in the US; generic launch price not disclosed. Not on the Medicare covered list.\n\nFornecimento — None current.",
            "unveiled_on": "2014-12-23",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Saxenda + generics",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Saxenda EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Saxenda EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Saxenda EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "3.0 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Saxenda EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -8,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "as published · NEJM 2015;373:11",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.6,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "as published · NEJM 2015;373:11",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -5.4,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "as published · NEJM 2015;373:11",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "SCALE Obesity and Prediabetes",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "as published · NEJM 2015;373:11",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 3731,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 56,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "SCALE, NEJM 2015;373:11",
                        "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                        "publisher": "nejm.org",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2015-07-02",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:32+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2014-12-23",
                    "date_precision": "day",
                    "indication_official": "Paediatric indication (12–17 years) added Dec 2020.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2015-03-23",
                    "date_precision": "day",
                    "indication_official": "Adults and adolescents from 12 years.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Saxenda EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2015-03-23",
                    "date_precision": "day",
                    "indication_official": "Licensed; NHS access limited.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved; date not retrievable.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado para a obesidade no Japão — apenas o produto para a diabetes.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado para o controlo do peso.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved; date not retrievable.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "withdrawn",
                    "decided_on": "2025-12-01",
                    "date_precision": "month",
                    "indication_official": null,
                    "note": "O Saxenda foi descontinuado na Austrália em dezembro de 2025 — uma retirada comercial, não uma ação regulamentar.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "qsymia",
            "name": "Phentermine / topiramate ER",
            "maker": "Vivus",
            "country": null,
            "region": null,
            "form": "Tablet",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "The clearest case of two competent regulators reading the same dossier and reaching opposite conclusions",
            "note": "Resultados clínicos — None. The required post-marketing cardiovascular trial was never completed.\n\nAdvertência em caixa — None — but the warnings are extensive.\n\nEfeitos adversos — Embryo-fetal toxicity including cleft lip and palate, suicidal ideation, acute angle-closure glaucoma, cognitive impairment, metabolic acidosis, kidney stones, slowed growth in adolescents. Paraesthesia 20%, dry mouth 19%.\n\nGenéricos — Generic available in the US since 2023–24.\n\nPreço — As low as about $63/month with coupons. Not Medicare-covered for obesity.\n\nFornecimento — None.",
            "unveiled_on": "2012-07-17",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Qsymia",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Sympathomimetic + anticonvulsant combination",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Tablet, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "7.5/46 mg or 15/92 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -9.8,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis, 15/92 mg · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -1.2,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis, 15/92 mg · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -8.6,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis, 15/92 mg · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "CONQUER",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis, 15/92 mg · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 2487,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 56,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "Label reports only all-cause withdrawal of 31–40%, which is not comparable to other drugs' figures",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2012-07-17",
                    "date_precision": "day",
                    "indication_official": "Paediatric indication added June 2022. Distributed under a REMS for embryo-fetal toxicity — certified pharmacies only.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Qsymia label, rev. 09/2024",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2024-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "refused",
                    "decided_on": "2013-02-21",
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Parecer negativo do CHMP em 18 de outubro de 2012, recusa confirmada em reexame. Fundamentos: efeitos cardiovasculares a longo prazo desconhecidos, efeitos psiquiátricos e cognitivos do topiramato, teratogenicidade e uma elevada probabilidade de uso off-label que não podia ser gerida.",
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Qsiva refusal question-and-answer document",
                        "url": "https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_en.pdf",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2013-02-21",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Sem licença; seguiu a recusa da UE.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não registado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não registado. A fentermina isolada está disponível como Duromine.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "contrave",
            "name": "Naltrexone / bupropion ER",
            "maker": "Currax; Orexigen Ireland",
            "country": null,
            "region": null,
            "form": "Tablet",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "One in four people stopped it because of side effects · Its outcomes trial was destroyed by the sponsor's own conduct",
            "note": "Resultados clínicos — The LIGHT cardiovascular outcomes trial was terminated early in 2015 after the sponsor's unauthorised disclosure of interim data, and never produced a valid result. The label states plainly that the cardiovascular effect has not been established.\n\nAdvertência em caixa — Suicidal thoughts and behaviours — the antidepressant class warning.\n\nEfeitos adversos — Seizure risk, blood pressure and heart rate increases, hepatotoxicity, angle-closure glaucoma, opioid blockade. Nausea 33%, constipation 19%, headache 18%.\n\nGenéricos — Generic available in the US.\n\nPreço — About $199/month with coupons. Not Medicare-covered for obesity.\n\nFornecimento — None.",
            "unveiled_on": "2014-09-10",
            "last_verified_at": "2026-08-21T08:38:32+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Contrave (US) / Mysimba (EU)",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Opioid antagonist + aminoketone antidepressant",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Tablet, twice daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "32 mg / 360 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -5.4,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -1.3,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -4.1,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "COR-I",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "FDA label analysis · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 1074,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 56,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": false,
                    "value": "24% vs 12% placebo — by far the highest of any approved agent",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2014-09-10",
                    "date_precision": "day",
                    "indication_official": "BMI ≥30, or ≥27 with a comorbidity.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Contrave label, rev. 03/2021",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2021-03-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2015-03-26",
                    "date_precision": "day",
                    "indication_official": "Mandatory stopping rule: discontinue at 16 weeks if less than 5% weight has been lost. Under additional monitoring for cardiovascular safety; 2024 EMA advisory on serious opioid interactions.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "EMA — Mysimba EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "2015-03-26",
                    "date_precision": "day",
                    "indication_official": "Licensed as Mysimba.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved; decision date not published in an accessible summary.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "approved",
                    "decided_on": "2019-01-01",
                    "date_precision": "month",
                    "indication_official": "Registered as Contrave. Not PBS-listed.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "orlistat",
            "name": "Orlistat",
            "maker": "Roche; Haleon; many generics",
            "country": null,
            "region": null,
            "form": "Capsule",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "The only approved obesity drug available without a prescription · Smallest effect of any approved agent, and the longest safety record",
            "note": "Resultados clínicos — No cardiovascular outcome trial. XENDOS showed a 42% reduction in progression to type 2 diabetes over four years, and that endpoint is in the label.\n\nAdvertência em caixa — None.\n\nEfeitos adversos — Oily spotting 27%, flatus with discharge 24%, faecal urgency 22%, faecal incontinence 8%. Post-marketing: severe liver injury; kidney stones and oxalate nephropathy warning added to alli.\n\nGenéricos — Extensively genericised worldwide, off patent.\n\nPreço — Brand about $430 per fill; alli about $87; generics cheaper.\n\nFornecimento — None.",
            "unveiled_on": "1999-04-26",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Xenical (Rx) / alli (OTC)",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Gastrointestinal lipase inhibitor",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Capsule, three times daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "120 mg with each fat-containing meal; 60 mg over the counter",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:32+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -5.17,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "4-year mean · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.75,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "4-year mean · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -2.42,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "4-year mean · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "XENDOS",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "4-year mean · FDA label §14",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 3305,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 208,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não declarado como valor específico de efeitos adversos",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:32+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "1999-04-26",
                    "date_precision": "day",
                    "indication_official": "alli 60 mg approved over the counter 7 Feb 2007.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Xenical label, rev. 11/2022",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2022-11-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "1998-07-29",
                    "date_precision": "day",
                    "indication_official": "Xenical centrally authorised 1998; alli 2007.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": "1998-07-29",
                    "date_precision": "day",
                    "indication_official": "Prescription 120 mg and pharmacy 60 mg.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved; date not retrievable.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "approved",
                    "decided_on": "2023-01-01",
                    "date_precision": "month",
                    "indication_official": "Approved as an over-the-counter product for visceral fat reduction — a distinct Japanese indication, not the Western obesity one.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "approved",
                    "decided_on": "2000-01-01",
                    "date_precision": "month",
                    "indication_official": "Registered.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "phentermine",
            "name": "Phentermine",
            "maker": "Multiple",
            "country": null,
            "region": null,
            "form": "Tablet",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Approved 67 years ago and still the cheapest option · The only one not licensed for long-term use, yet often used that way",
            "note": "Resultados clínicos — None.\n\nAdvertência em caixa — None, but the label warns of primary pulmonary hypertension — described in the label as a rare, frequently fatal lung disease — and serious regurgitant cardiac valvular disease.\n\nEfeitos adversos — Abuse and dependence potential; tolerance develops.\n\nGenéricos — Long off patent, extremely cheap.\n\nPreço — As low as about $16/month in the US.\n\nFornecimento — None.",
            "unveiled_on": "1959-01-01",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Adipex-P, Lomaira, Duromine",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Adipex-P label, rev. 01/2012",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2012-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Sympathomimetic amine anorectic",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Adipex-P label, rev. 01/2012",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2012-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Tablet, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Adipex-P label, rev. 01/2012",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2012-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "37.5 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Adipex-P label, rev. 01/2012",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2012-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": true,
                    "reason": "Aprovado em 1959, antes dos padrões modernos de ensaios clínicos. Não existe no folheto qualquer ensaio pivotal contemporâneo controlado por placebo com um endpoint de variação percentual do peso corporal. A literatura sugere uma perda de cerca de 3 a 5 kg descontado o placebo ao longo de 12 a 36 semanas, o que não é um valor confirmado pelo folheto.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Aprovado em 1959, antes dos padrões modernos de ensaios clínicos. Não existe no folheto qualquer ensaio pivotal contemporâneo controlado por placebo com um endpoint de variação percentual do peso corporal. A literatura sugere uma perda de cerca de 3 a 5 kg descontado o placebo ao longo de 12 a 36 semanas, o que não é um valor confirmado pelo folheto.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Aprovado em 1959, antes dos padrões modernos de ensaios clínicos. Não existe no folheto qualquer ensaio pivotal contemporâneo controlado por placebo com um endpoint de variação percentual do peso corporal. A literatura sugere uma perda de cerca de 3 a 5 kg descontado o placebo ao longo de 12 a 36 semanas, o que não é um valor confirmado pelo folheto.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "O promotor não identificou o ensaio pivotal.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A dimensão da amostra do ensaio não foi divulgada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "A duração do ensaio não foi publicada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "1959-01-01",
                    "date_precision": "month",
                    "indication_official": "Schedule IV controlled substance. Indicated for SHORT-TERM use only — “a few weeks”. It is the only US obesity drug not indicated for chronic use, so long-term prescribing is off-label.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Adipex-P label, rev. 01/2012",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2012-01-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Sem autorização centralizada. Um procedimento de arbitragem da EMA em 2000 restringiu ou retirou muitos anorexígenos em toda a UE.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Sem licença.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não registado no Brasil.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved for short-term use.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Registered as Duromine / Metermine.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "setmelanotide",
            "name": "Setmelanotide",
            "maker": "Rhythm Pharmaceuticals",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Not a general obesity drug — it treats specific genetic and acquired defects in the melanocortin pathway · Shows what obesity medicine looks like when the mechanism is known precisely",
            "note": "Resultados clínicos — None; the populations are too small.\n\nAdvertência em caixa — None.\n\nEfeitos adversos — Skin hyperpigmentation, nausea, vomiting, headache in over 20%. Depression and suicidal ideation monitoring; spontaneous penile erections.\n\nGenéricos — None; orphan exclusivity.\n\nPreço — About $3,706 per vial in the US. Annual cost widely reported in the high six figures but not corroborated by a primary source.\n\nFornecimento — None.",
            "unveiled_on": "2020-11-25",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Imcivree",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "MC4R agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "Titrated by age and weight, up to 3 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -15.8,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "mean BMI change · Rhythm / FDA approval",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": 2.6,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "mean BMI change · Rhythm / FDA approval",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -18.4,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "mean BMI change · Rhythm / FDA approval",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "TRANSCEND",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "mean BMI change · Rhythm / FDA approval",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 142,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 52,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2020-11-25",
                    "date_precision": "day",
                    "indication_official": "For genetically confirmed POMC, PCSK1 or LEPR deficiency; Bardet–Biedl syndrome added 2022; acquired hypothalamic obesity added 19 Mar 2026.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2026-03-27",
                    "date_precision": "day",
                    "indication_official": "Covers the genetic indications. For acquired hypothalamic obesity: CHMP positive opinion 27 Mar 2026, European Commission authorisation announced 1 May 2026. EMA does not publish the Commission decision date, so we carry the opinion date.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Imcivree EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Licensed for the genetic obesity indications; status of the hypothalamic obesity extension not established.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada; existe uma avaliação farmacoeconómica, o que sugere uma submissão.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "metreleptin",
            "name": "Metreleptin",
            "maker": "Amryt / Chiesi",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "confirmed",
            "subtitle": "Routinely miscategorised as an obesity drug — it is a replacement therapy for a hormone people are missing",
            "note": "Resultados clínicos — None.\n\nAdvertência em caixa — Two components: neutralising anti-metreleptin antibodies that can cause loss of efficacy and severe infection; and risk of T-cell lymphoma. Available only through a restricted programme.\n\nEfeitos adversos — Headache, hypoglycaemia, abdominal pain.\n\nGenéricos — None.\n\nPreço — Not disclosed in any primary source. Widely reported above $700,000 a year.\n\nFornecimento — None.",
            "unveiled_on": "2014-02-24",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Myalept (US) / Myalepta (EU)",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Recombinant leptin analogue",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "Up to 10 mg daily",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": true,
                    "reason": "Não existe nenhum ensaio aleatorizado controlado por placebo, e por desenho — a doença é demasiado rara. Um valor ajustado ao placebo não pode existir para este medicamento.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Não existe nenhum ensaio aleatorizado controlado por placebo, e por desenho — a doença é demasiado rara. Um valor ajustado ao placebo não pode existir para este medicamento.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Não existe nenhum ensaio aleatorizado controlado por placebo, e por desenho — a doença é demasiado rara. Um valor ajustado ao placebo não pode existir para este medicamento.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": false,
                    "value": "NIH open-label cohort",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 107,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "A duração do ensaio não foi publicada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "approved",
                    "decided_on": "2014-02-24",
                    "date_precision": "day",
                    "indication_official": "Only for complications of leptin deficiency in generalised lipodystrophy. The label explicitly excludes partial lipodystrophy, liver disease, HIV-related lipodystrophy and metabolic disease without generalised lipodystrophy.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "FDA — Myalept label",
                        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                        "publisher": "FDA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2014-02-24",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "ema",
                    "state": "approved",
                    "decided_on": "2018-07-30",
                    "date_precision": "day",
                    "indication_official": "Broader than the US: also covers familial and acquired partial lipodystrophy from age 12 where standard treatment has failed.",
                    "note": null,
                    "confidence": "confirmed",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "EMA — Myalepta EPAR",
                        "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta",
                        "publisher": "EMA",
                        "kind": "regulator",
                        "primary": true,
                        "published_on": "2026-08-20",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "mhra",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Licensed.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "approved",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": "Approved for lipodystrophy.",
                    "note": null,
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Nenhuma aprovação encontrada.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "mazdutide",
            "name": "Mazdutide",
            "maker": "Innovent Biologics",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "stated",
            "subtitle": "“Approved in China” is not “approved” — this is a common grey-market talking point",
            "note": "Resultados clínicos — None.\n\nAdvertência em caixa — Not established in an accessible label.\n\nEfeitos adversos — Gastrointestinal effects predominate. Glucagon agonism raises theoretical questions about heart rate and hepatic effects. Incidence figures not in an accessible primary source.\n\nGenéricos — None.\n\nPreço — Not corroborated.\n\nFornecimento — Not known.",
            "unveiled_on": "2025-06-27",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Xin Er Mei (信尔美)",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Innovent — NMPA approval for chronic weight management",
                        "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                        "publisher": "Innovent",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2025-06-27",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "Dual glucagon + GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Innovent — NMPA approval for chronic weight management",
                        "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                        "publisher": "Innovent",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2025-06-27",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, weekly",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Innovent — NMPA approval for chronic weight management",
                        "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                        "publisher": "Innovent",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2025-06-27",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "4 mg or 6 mg weekly",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Innovent — NMPA approval for chronic weight management",
                        "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                        "publisher": "Innovent",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2025-06-27",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -14.8,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "efficacy estimand, 6 mg · Innovent / Drugs 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                        "publisher": "Mazdutide: First Approval, Drugs 2025",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -0.5,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "efficacy estimand, 6 mg · Innovent / Drugs 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                        "publisher": "Mazdutide: First Approval, Drugs 2025",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -14.3,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "efficacy estimand, 6 mg · Innovent / Drugs 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                        "publisher": "Mazdutide: First Approval, Drugs 2025",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "GLORY-1",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "efficacy estimand, 6 mg · Innovent / Drugs 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                        "publisher": "Mazdutide: First Approval, Drugs 2025",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A dimensão da amostra do ensaio não foi divulgada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 48,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                        "publisher": "Mazdutide: First Approval, Drugs 2025",
                        "kind": "journal",
                        "primary": true,
                        "published_on": "2025-09-01",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "ema",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "approved",
                    "decided_on": "2025-06-27",
                    "date_precision": "day",
                    "indication_official": "First dual glucagon/GLP-1 agonist approved anywhere. Date is the sponsor's announcement date — NMPA's own database is not machine-accessible, so the regulator's decision date could not be independently confirmed. Note the China-specific thresholds: BMI ≥28 for obesity, ≥24 with a comorbidity — lower than the Western 30 and 27.",
                    "note": null,
                    "confidence": "stated",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Innovent — NMPA approval for chronic weight management",
                        "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                        "publisher": "Innovent",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2025-06-27",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "ecnoglutide",
            "name": "Ecnoglutide",
            "maker": "Sciwind Biosciences",
            "country": null,
            "region": null,
            "form": "Injection",
            "status": "approved",
            "evidence": "stated",
            "subtitle": "Approved on data that has never been peer-reviewed and whose sample size is undisclosed",
            "note": "Resultados clínicos — None.\n\nAdvertência em caixa — Not established in an accessible label.\n\nEfeitos adversos — Not published in an accessible primary source.\n\nGenéricos — None.\n\nPreço — Not disclosed.\n\nFornecimento — Not known.",
            "unveiled_on": "2026-03-06",
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "brand": {
                    "absent": false,
                    "value": "Ecnoglutide (brand not disclosed)",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "drug_class": {
                    "absent": false,
                    "value": "cAMP-biased GLP-1 receptor agonist",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "route": {
                    "absent": false,
                    "value": "Injection, weekly",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "dose": {
                    "absent": false,
                    "value": "2.4 mg weekly",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -15.4,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "company-reported · Sciwind release",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -0.3,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "company-reported · Sciwind release",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -15.1,
                    "unit": "pp",
                    "confidence": "stated",
                    "qualifier": "company-reported · Sciwind release",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "SLIMMER",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "company-reported · Sciwind release",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A dimensão da amostra do ensaio não foi divulgada.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 48,
                    "unit": "weeks",
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "discontinuation": {
                    "absent": true,
                    "reason": "Não publicado",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                }
            },
            "approvals": [
                {
                    "agency": "fda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "ema",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "mhra",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "anvisa",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "pmda",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "nmpa",
                    "state": "approved",
                    "decided_on": "2026-03-06",
                    "date_precision": "day",
                    "indication_official": "Chronic weight management in Chinese adults with overweight or obesity. Date comes from the sponsor's announcement; NMPA's database is not machine-accessible, so it is not regulator-confirmed.",
                    "note": null,
                    "confidence": "stated",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Sciwind — NMPA approval of ecnoglutide",
                        "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                        "publisher": "Sciwind",
                        "kind": "press",
                        "primary": false,
                        "published_on": "2026-03-06",
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                {
                    "agency": "hc",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                },
                {
                    "agency": "tga",
                    "state": "none",
                    "decided_on": null,
                    "date_precision": "day",
                    "indication_official": null,
                    "note": "Não aprovado.",
                    "confidence": "claim",
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            ]
        },
        {
            "slug": "retatrutide",
            "name": "Retatrutide",
            "maker": "Eli Lilly",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-3",
            "evidence": "stated",
            "subtitle": "Triple GLP-1 / GIP / glucagon agonist",
            "note": "Filing slipped to Q1 2027 for manufacturing and quality data. The cardiovascular outcomes trial does not complete until Feb 2029.\n\nTRIUMPH-2 and -3, in people with diabetes and with cardiovascular disease, came in materially lower at roughly 21% and 23%. A dysesthesia signal appeared in 8.8–20.9% of participants in TRIUMPH-4 versus 0.7% on placebo.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Triple GLP-1 / GIP / glucagon agonist",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -28.3,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.2,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -26.1,
                    "unit": "pp",
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "TRIUMPH-1",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 2339,
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 80,
                    "unit": "weeks",
                    "confidence": "stated",
                    "qualifier": "TRIUMPH-1, N=2,339, 80 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Retatrutide — Eli Lilly",
                        "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                        "publisher": "Retatrutide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "cagrisema",
            "name": "CagriSema",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": null,
            "status": "filed",
            "evidence": "claim",
            "subtitle": "Amylin analogue + GLP-1 agonist",
            "note": "US application submitted 18 Dec 2025; no confirmed decision date. No EU submission verifiable from EMA sources.\n\nREDEFINE 4, the head-to-head against tirzepatide, MISSED its primary endpoint on 23 Feb 2026 — non-inferiority was not demonstrated. This is the single most under-reported fact in consumer coverage of this drug.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Amylin analogue + GLP-1 agonist",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -20.4,
                    "unit": "%",
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -3,
                    "unit": "%",
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -17.4,
                    "unit": "pp",
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "REDEFINE 1",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 3417,
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 68,
                    "unit": "weeks",
                    "confidence": "claim",
                    "qualifier": "REDEFINE 1, N=3,417, 68 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "CagriSema — Novo Nordisk",
                        "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                        "publisher": "CagriSema",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "amycretin",
            "name": "Amycretin",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "claim",
            "subtitle": "Single molecule acting on GLP-1 and amylin receptors",
            "note": "Phase 3 announced for Q1 2026, but no Phase 3 obesity trial is findable on ClinicalTrials.gov.\n\nTreat any claim of amycretin Phase 3 data as non-existent. The figure here comes from a small early trial and will very likely shrink at scale.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Single molecule acting on GLP-1 and amylin receptors",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -22,
                    "unit": "%",
                    "confidence": "claim",
                    "qualifier": "N=125, up to 36 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": 2,
                    "unit": "%",
                    "confidence": "claim",
                    "qualifier": "N=125, up to 36 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -24,
                    "unit": "pp",
                    "confidence": "claim",
                    "qualifier": "N=125, up to 36 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": true,
                    "reason": "O promotor não identificou o ensaio.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": false,
                    "value": 125,
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "N=125, up to 36 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 36,
                    "unit": "weeks",
                    "confidence": "claim",
                    "qualifier": "N=125, up to 36 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Amycretin — Novo Nordisk",
                        "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                        "publisher": "Amycretin",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "bimagrumab-semaglutide",
            "name": "Bimagrumab + semaglutide",
            "maker": "Eli Lilly",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "claim",
            "subtitle": "Anti-activin receptor antibody, muscle-sparing, combined with a GLP-1",
            "note": "One Phase 2 in obesity with diabetes was withdrawn before enrolling anyone, for stated strategic reasons.\n\nThe interesting endpoint here is not the weight number but its composition: 92.8% of the loss was fat, with lean mass preserved. Bimagrumab alone added 2.5 kg of lean mass. Comparator arms in the same trial: semaglutide alone −15.7%.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Anti-activin receptor antibody, muscle-sparing, combined with a GLP-1",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Bimagrumab + semaglutide — Eli Lilly",
                        "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                        "publisher": "Bimagrumab + semaglutide",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -22.1,
                    "unit": "%",
                    "confidence": "claim",
                    "qualifier": "BELIEVE, N=507, 72 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Bimagrumab + semaglutide — Eli Lilly",
                        "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                        "publisher": "Bimagrumab + semaglutide",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "O braço de placebo não foi publicado para esta leitura de resultados.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Não é possível calcular um valor ajustado ao placebo: o braço de placebo não foi publicado.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": false,
                    "value": "BELIEVE",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "BELIEVE, N=507, 72 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Bimagrumab + semaglutide — Eli Lilly",
                        "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                        "publisher": "Bimagrumab + semaglutide",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 507,
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "BELIEVE, N=507, 72 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Bimagrumab + semaglutide — Eli Lilly",
                        "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                        "publisher": "Bimagrumab + semaglutide",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 72,
                    "unit": "weeks",
                    "confidence": "claim",
                    "qualifier": "BELIEVE, N=507, 72 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Bimagrumab + semaglutide — Eli Lilly",
                        "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                        "publisher": "Bimagrumab + semaglutide",
                        "kind": "trade",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "aleniglipron",
            "name": "Aleniglipron",
            "maker": "Structure Therapeutics",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "stated",
            "subtitle": "Oral small-molecule GLP-1 agonist",
            "note": "Phase 3 from H2 2026.\n\nFigure quoted is already placebo-adjusted. Small trial; 3.7% discontinued for adverse events among those escalated.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Oral small-molecule GLP-1 agonist",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Aleniglipron — Structure Therapeutics",
                        "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                        "publisher": "Aleniglipron",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -16.3,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "ACCESS II, N=85, 44 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Aleniglipron — Structure Therapeutics",
                        "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                        "publisher": "Aleniglipron",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "O braço de placebo não foi publicado para esta leitura de resultados.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Não é possível calcular um valor ajustado ao placebo: o braço de placebo não foi publicado.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": false,
                    "value": "ACCESS II",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "ACCESS II, N=85, 44 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Aleniglipron — Structure Therapeutics",
                        "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                        "publisher": "Aleniglipron",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 85,
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "ACCESS II, N=85, 44 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Aleniglipron — Structure Therapeutics",
                        "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                        "publisher": "Aleniglipron",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 44,
                    "unit": "weeks",
                    "confidence": "stated",
                    "qualifier": "ACCESS II, N=85, 44 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Aleniglipron — Structure Therapeutics",
                        "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                        "publisher": "Aleniglipron",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "maritide",
            "name": "MariTide",
            "maker": "Amgen",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "confirmed",
            "subtitle": "GIP receptor antagonist conjugated to a GLP-1 agonist",
            "note": "Phase 3 running; primary completions Jan 2027. Cardiovascular outcomes trial to Jun 2028.\n\nDosed monthly rather than weekly, which is the point of the molecule. No Phase 3 efficacy readout exists — any claim of one circulating now is unsupported.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "GIP receptor antagonist conjugated to a GLP-1 agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -16.2,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "N=592, 52 weeks, NEJM Sep 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -2.5,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "N=592, 52 weeks, NEJM Sep 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -13.7,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "N=592, 52 weeks, NEJM Sep 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": true,
                    "reason": "O promotor não identificou o ensaio.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": false,
                    "value": 592,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "N=592, 52 weeks, NEJM Sep 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 52,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": "N=592, 52 weeks, NEJM Sep 2025",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "MariTide — Amgen",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                        "publisher": "MariTide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "survodutide",
            "name": "Survodutide",
            "maker": "Boehringer Ingelheim / Zealand",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-3",
            "evidence": "confirmed",
            "subtitle": "Dual glucagon + GLP-1 agonist",
            "note": "No regulatory filing announced.\n\nA textbook estimand problem. The widely-quoted “16.6%” is the trial-product estimand — people who kept taking it. The NEJM primary analysis, counting everyone randomised, is −13.0% against a −5.4% placebo arm. Both numbers are honest; only one describes real-world use.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Dual glucagon + GLP-1 agonist",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -13,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -5.4,
                    "unit": "%",
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -7.6,
                    "unit": "pp",
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "SYNCHRONIZE-1",
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 725,
                    "unit": null,
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 76,
                    "unit": "weeks",
                    "confidence": "confirmed",
                    "qualifier": "SYNCHRONIZE-1, N=725, 76 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Survodutide — Boehringer Ingelheim / Zealand",
                        "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                        "publisher": "Survodutide",
                        "kind": "journal",
                        "primary": true,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "vk2735-oral",
            "name": "VK2735 (oral)",
            "maker": "Viking Therapeutics",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "stated",
            "subtitle": "Dual GLP-1 / GIP agonist",
            "note": "Phase 3 is running on the injectable formulation, not this one.\n\nOnly 13 weeks. Short trials flatter weight-loss drugs, because the curve has not yet flattened.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Dual GLP-1 / GIP agonist",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -12.2,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -1.3,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -10.9,
                    "unit": "pp",
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "VENTURE-Oral",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 280,
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 13,
                    "unit": "weeks",
                    "confidence": "stated",
                    "qualifier": "VENTURE-Oral, N=280, 13 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "VK2735 (oral) — Viking Therapeutics",
                        "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                        "publisher": "VK2735 (oral)",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "petrelintide",
            "name": "Petrelintide",
            "maker": "Zealand Pharma / Roche",
            "country": null,
            "region": null,
            "form": null,
            "status": "phase-2",
            "evidence": "stated",
            "subtitle": "Long-acting amylin analogue",
            "note": "Phase 3 to start H2 2026.\n\nThe headline here is tolerability, not size: discontinuation for adverse events was 4.8% against 4.9% on placebo, with no vomiting at the maximally effective dose. If that holds, it changes who can stay on treatment.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "drug_class": {
                    "absent": false,
                    "value": "Long-acting amylin analogue",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": null,
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "weight_change": {
                    "absent": false,
                    "value": -10.7,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_change": {
                    "absent": false,
                    "value": -1.7,
                    "unit": "%",
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "placebo_adjusted": {
                    "absent": false,
                    "value": -9,
                    "unit": "pp",
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial": {
                    "absent": false,
                    "value": "ZUPREME-1",
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_n": {
                    "absent": false,
                    "value": 493,
                    "unit": null,
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                },
                "trial_weeks": {
                    "absent": false,
                    "value": 42,
                    "unit": "weeks",
                    "confidence": "stated",
                    "qualifier": "ZUPREME-1, N=493, 42 weeks",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": {
                        "title": "Petrelintide — Zealand Pharma / Roche",
                        "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                        "publisher": "Petrelintide",
                        "kind": "press",
                        "primary": false,
                        "published_on": null,
                        "retrieved_at": "2026-08-20T00:00:00+00:00"
                    }
                }
            }
        },
        {
            "slug": "bpc-157",
            "name": "BPC-157",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Healing, gut health, tendon repair",
            "note": "Evidência — Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.\n\nEstatuto regulamentar — Unapproved drug. Removed from the FDA's significant-safety-risk list around 22 Apr 2026 — which does not make it legal to compound. An advisory panel voted 8–6 to recommend adding it to the compounding list on 23 Jul 2026; that vote is non-binding and rulemaking has not begun.\n\nAMA (WADA) — Prohibited at all times (S0)\n\nRiscos conhecidos — FDA cited immunogenicity risk and impurities. No human safety database exists to characterise the risk.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Nenhum ensaio aleatorizado em humanos concluído e publicado. O registo tem três entradas: uma Fase 1 de 2015 cujos dados foram retirados antes da revisão por pares, um ensaio de Fase 2 em isquiotibiais ainda a recrutar, e um estudo sem relação. As cerca de 200 entradas na PubMed são quase todas trabalho em animais de um único grupo de investigação.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "tb-500",
            "name": "TB-500",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Recovery, tissue repair",
            "note": "Evidência — O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.\n\nEstatuto regulamentar — Unapproved. Same April 2026 list removal and same July 2026 advisory vote as BPC-157, with the same legal effect: none.\n\nAMA (WADA) — Prohibited (S2.3, growth factors)\n\nRiscos conhecidos — No human safety dataset for the fragment.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:33+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "O fragmento vendido como TB-500 tem exatamente um ensaio humano registado, ainda a recrutar e sem resultados. A timosina β4 completa — uma molécula diferente — tem de facto ensaios reais de Fase 2 e Fase 3, nenhum dos quais conduziu a qualquer aprovação. Confundir as duas é a manobra de marketing habitual.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "ipamorelin",
            "name": "Ipamorelin",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Growth hormone release, body composition",
            "note": "Evidência — Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.\n\nEstatuto regulamentar — Still on the FDA's significant-safety-risk list. FDA cites immunogenicity risk and serious adverse events including death with intravenous administration. It is the only compound here the agency kept on that list in 2026.\n\nAMA (WADA) — Prohibited (S2.2.4, growth hormone secretagogues)\n\nRiscos conhecidos — The only one on this list FDA has affirmatively kept flagged for safety.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:33+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "negative",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Dois ensaios aleatorizados, ambos em íleo pós-operatório, ambos sem sucesso; o programa foi abandonado. Mais um estudo de farmacologia em voluntários, de 1999. Não existe qualquer ensaio aleatorizado para composição corporal, cicatrização ou longevidade.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:33+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "cjc-1295",
            "name": "CJC-1295",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Growth hormone release",
            "note": "Evidência — Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.\n\nEstatuto regulamentar — Unapproved; no approved medical use anywhere.\n\nAMA (WADA) — Prohibited (S2.2.4, GHRH analogues)\n\nRiscos conhecidos — Sustained growth hormone and IGF-1 elevation is the mechanism of concern.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Um ensaio registado, em obesidade visceral associada ao VIH, terminado. Mais nada. Não há evidência humana positiva de eficácia para nenhuma das utilizações promovidas.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "mots-c",
            "name": "MOTS-c",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Metabolic health, longevity",
            "note": "Evidência — Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.\n\nEstatuto regulamentar — Unapproved. Removed from the safety-risk list Apr 2026; advisory vote 7–5 in Jul 2026; not compoundable.\n\nAMA (WADA) — Prohibited (S0; classed as a metabolic modulator in some national renderings)\n\nRiscos conhecidos — Nothing characterised — there is no human exposure dataset.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Nenhum ensaio aleatorizado de MOTS-c administrado em humanos. Há uma Fase 2 em pré-diabetes a recrutar, sem resultados. Todos os outros registos medem o MOTS-c de ocorrência natural ou estudam exercício físico.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "epitalon",
            "name": "Epitalon",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Longevity, telomeres",
            "note": "Evidência — Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.\n\nEstatuto regulamentar — Unapproved; not compoundable.\n\nAMA (WADA) — Prohibited (S0)\n\nRiscos conhecidos — Nothing characterised.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Zero ensaios humanos registados no ClinicalTrials.gov. A literatura de apoio é sobretudo trabalho antigo em língua russa, fora dos registos internacionais.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "ghk-cu-injected",
            "name": "GHK-Cu (injected)",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Skin, healing, anti-ageing",
            "note": "Evidência — A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.\n\nEstatuto regulamentar — Injectable routes removed from the safety-risk list Apr 2026; not compoundable. Topical cosmetic use is a separate regulatory category.\n\nAMA (WADA) — Injectable use captured by S0\n\nRiscos conhecidos — Copper load with repeated injection is an unstudied hazard.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "topical only",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "A evidência humana que existe é tópica e escassa: um pequeno estudo em pele do rosto e um ensaio com gel para feridas ainda a recrutar. Não existe qualquer ensaio aleatorizado de GHK-Cu injetado em humanos.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "aod-9604",
            "name": "AOD-9604",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Fat loss",
            "note": "Evidência — Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.\n\nEstatuto regulamentar — Unapproved.\n\nAMA (WADA) — Prohibited (S2.2.3, growth hormone fragments)\n\nRiscos conhecidos — Nothing characterised.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Zero ensaios registados e zero ensaios aleatorizados na PubMed. O desenvolvimento para a obesidade foi abandonado. A literatura existente resume-se a artigos sobre métodos de deteção de doping.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "semax-selank",
            "name": "Semax / Selank",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Cognition, anxiety",
            "note": "Evidência — Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.\n\nEstatuto regulamentar — Unapproved; not compoundable.\n\nAMA (WADA) — Captured by S0\n\nRiscos conhecidos — Nothing characterised.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "none",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "Semax: zero ensaios registados; um artigo russo de 2007 sobre doença do neurónio motor. Selank: zero ensaios registados, e não existe sequer um ensaio aleatorizado em língua inglesa.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "tesamorelin",
            "name": "Tesamorelin",
            "maker": null,
            "country": null,
            "region": null,
            "form": null,
            "status": "preclinical",
            "evidence": "claim",
            "subtitle": "Abdominal fat reduction",
            "note": "Evidência — A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.\n\nEstatuto regulamentar — APPROVED in the US as Egrifta, NDA 022505, for HIV-associated lipodystrophy only.\n\nAMA (WADA) — Prohibited (S2.2.4)\n\nRiscos conhecidos — Its own label states it is not indicated for weight loss and is weight-neutral. Contraindicated in active malignancy. In trials, 5% developed an HbA1c of 6.5% or above versus 1% on placebo — a hazard ratio of 3.3 for developing diabetes.",
            "unveiled_on": null,
            "last_verified_at": "2026-08-21T08:38:34+00:00",
            "values": {
                "weight_change": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_change": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "placebo_adjusted": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_n": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "trial_weeks": {
                    "absent": true,
                    "reason": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "confidence": "absent",
                    "verified_at": "2026-08-21T08:38:34+00:00"
                },
                "human_rct": {
                    "absent": false,
                    "value": "yes",
                    "unit": null,
                    "confidence": "claim",
                    "qualifier": "A exceção desta lista. Evidência real de Fase 3, N=412 mais uma extensão, e uma aprovação da FDA — para uma única indicação estreita: redução do excesso de gordura abdominal em pessoas com lipodistrofia associada ao VIH.",
                    "observed_on": null,
                    "verified_at": "2026-08-21T08:38:34+00:00",
                    "citation": null
                }
            }
        },
        {
            "slug": "redefine-4",
            "name": "REDEFINE 4",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Falhou o endpoint primário",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2026-02-23",
                "reason": "Não se demonstrou que o CagriSema fosse não inferior ao tirzepatido 15 mg em comparação direta: −23,0% contra −25,5%."
            }
        },
        {
            "slug": "bimagrumab-tirzepatide",
            "name": "Bimagrumab + tirzepatide",
            "maker": "Eli Lilly",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Retirado sem um único participante inscrito",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2025-09-25",
                "reason": "Razões estratégicas declaradas. Contexto: os reguladores esperam agora que os agentes poupadores de músculo demonstrem perda de peso em acréscimo a um GLP-1, e não meramente ao lado dele."
            }
        },
        {
            "slug": "nnc0519-0130",
            "name": "NNC0519-0130",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Descontinuado apesar de ter atingido o endpoint",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2025-08-06",
                "reason": "«Considerações de portefólio.» Atingiu o endpoint de perda de peso na Fase 2 e foi cancelado à mesma — um lembrete de que funcionar e chegar aos doentes são perguntas diferentes."
            }
        },
        {
            "slug": "zalfermin",
            "name": "Zalfermin",
            "maker": "Novo Nordisk",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Descontinuado",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2025-08-06",
                "reason": "Fracasso de Fase 2 na MASH."
            }
        },
        {
            "slug": "ct-173",
            "name": "CT-173",
            "maker": "Roche",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Abandonado",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2025-07-24",
                "reason": "Um mimético do PYY abandonado porque «a capacidade de desenvolvimento e a competitividade simplesmente não estavam lá»."
            }
        },
        {
            "slug": "danuglipron",
            "name": "Danuglipron",
            "maker": "Pfizer",
            "country": null,
            "region": null,
            "form": null,
            "status": "discontinued",
            "evidence": null,
            "subtitle": "Descontinuado",
            "note": null,
            "unveiled_on": null,
            "last_verified_at": null,
            "values": [],
            "retired": {
                "on": "2025-04-14",
                "reason": "Potencial lesão hepática induzida pelo medicamento num participante do ensaio. É o segundo GLP-1 oral da Pfizer a morrer de um sinal hepático, depois do lotiglipron em 2023."
            }
        }
    ],
    "changelog": [
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Duration",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Participants",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Pivotal trial",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Placebo-adjusted",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Placebo arm",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Weight change",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tesamorelin · Randomised human evidence",
            "entity": "tesamorelin",
            "summary": "Tesamorelin: Evidência humana aleatorizada registado como yes.",
            "old": null,
            "new": "yes",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Duration",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Participants",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Pivotal trial",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Placebo-adjusted",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Placebo arm",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Weight change",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semax / Selank · Randomised human evidence",
            "entity": "semax-selank",
            "summary": "Semax / Selank: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Duration",
            "entity": "aod-9604",
            "summary": "AOD-9604: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Participants",
            "entity": "aod-9604",
            "summary": "AOD-9604: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Pivotal trial",
            "entity": "aod-9604",
            "summary": "AOD-9604: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Placebo-adjusted",
            "entity": "aod-9604",
            "summary": "AOD-9604: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Placebo arm",
            "entity": "aod-9604",
            "summary": "AOD-9604: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Weight change",
            "entity": "aod-9604",
            "summary": "AOD-9604: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "AOD-9604 · Randomised human evidence",
            "entity": "aod-9604",
            "summary": "AOD-9604: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Duration",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Participants",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Pivotal trial",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Placebo-adjusted",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Placebo arm",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Weight change",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "GHK-Cu (injected) · Randomised human evidence",
            "entity": "ghk-cu-injected",
            "summary": "GHK-Cu (injected): Evidência humana aleatorizada registado como topical only.",
            "old": null,
            "new": "topical only",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Duration",
            "entity": "epitalon",
            "summary": "Epitalon: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Participants",
            "entity": "epitalon",
            "summary": "Epitalon: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Pivotal trial",
            "entity": "epitalon",
            "summary": "Epitalon: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Placebo-adjusted",
            "entity": "epitalon",
            "summary": "Epitalon: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Placebo arm",
            "entity": "epitalon",
            "summary": "Epitalon: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Weight change",
            "entity": "epitalon",
            "summary": "Epitalon: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Epitalon · Randomised human evidence",
            "entity": "epitalon",
            "summary": "Epitalon: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Duration",
            "entity": "mots-c",
            "summary": "MOTS-c: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Participants",
            "entity": "mots-c",
            "summary": "MOTS-c: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Pivotal trial",
            "entity": "mots-c",
            "summary": "MOTS-c: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Placebo-adjusted",
            "entity": "mots-c",
            "summary": "MOTS-c: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Placebo arm",
            "entity": "mots-c",
            "summary": "MOTS-c: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Weight change",
            "entity": "mots-c",
            "summary": "MOTS-c: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MOTS-c · Randomised human evidence",
            "entity": "mots-c",
            "summary": "MOTS-c: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Duration",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Participants",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Pivotal trial",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Placebo-adjusted",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Placebo arm",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Weight change",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CJC-1295 · Randomised human evidence",
            "entity": "cjc-1295",
            "summary": "CJC-1295: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Duration",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Participants",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Pivotal trial",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Placebo-adjusted",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Placebo arm",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Weight change",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ipamorelin · Randomised human evidence",
            "entity": "ipamorelin",
            "summary": "Ipamorelin: Evidência humana aleatorizada registado como negative.",
            "old": null,
            "new": "negative",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Duration",
            "entity": "tb-500",
            "summary": "TB-500: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Participants",
            "entity": "tb-500",
            "summary": "TB-500: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Pivotal trial",
            "entity": "tb-500",
            "summary": "TB-500: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Placebo-adjusted",
            "entity": "tb-500",
            "summary": "TB-500: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Placebo arm",
            "entity": "tb-500",
            "summary": "TB-500: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Weight change",
            "entity": "tb-500",
            "summary": "TB-500: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "TB-500 · Randomised human evidence",
            "entity": "tb-500",
            "summary": "TB-500: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Duration",
            "entity": "bpc-157",
            "summary": "BPC-157: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Participants",
            "entity": "bpc-157",
            "summary": "BPC-157: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Pivotal trial",
            "entity": "bpc-157",
            "summary": "BPC-157: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Placebo-adjusted",
            "entity": "bpc-157",
            "summary": "BPC-157: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Placebo arm",
            "entity": "bpc-157",
            "summary": "BPC-157: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Weight change",
            "entity": "bpc-157",
            "summary": "BPC-157: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "BPC-157 · Randomised human evidence",
            "entity": "bpc-157",
            "summary": "BPC-157: Evidência humana aleatorizada registado como none.",
            "old": null,
            "new": "none",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Placebo-adjusted",
            "entity": "petrelintide",
            "summary": "Petrelintide: Ajustado ao placebo registado como -9,0 pp.",
            "old": null,
            "new": "-9.0 pp",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Placebo arm",
            "entity": "petrelintide",
            "summary": "Petrelintide: Braço de placebo registado como -1,7 %.",
            "old": null,
            "new": "-1.7 %",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Weight change",
            "entity": "petrelintide",
            "summary": "Petrelintide: Variação de peso registado como -10,7 %.",
            "old": null,
            "new": "-10.7 %",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Duration",
            "entity": "petrelintide",
            "summary": "Petrelintide: Duração registado como 42 weeks.",
            "old": null,
            "new": "42 weeks",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Participants",
            "entity": "petrelintide",
            "summary": "Petrelintide: Participantes registado como 493.",
            "old": null,
            "new": "493",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Pivotal trial",
            "entity": "petrelintide",
            "summary": "Petrelintide: Ensaio pivotal registado como ZUPREME-1.",
            "old": null,
            "new": "ZUPREME-1",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Petrelintide · Class",
            "entity": "petrelintide",
            "summary": "Petrelintide: Classe registado como Long-acting amylin analogue.",
            "old": null,
            "new": "Long-acting amylin analogue",
            "citation": {
                "title": "Petrelintide — Zealand Pharma / Roche",
                "url": "https://www.zealandpharma.com/pipeline/petrelintide/",
                "publisher": "Petrelintide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Placebo-adjusted",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Ajustado ao placebo registado como -10,9 pp.",
            "old": null,
            "new": "-10.9 pp",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Placebo arm",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Braço de placebo registado como -1,3 %.",
            "old": null,
            "new": "-1.3 %",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Weight change",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Variação de peso registado como -12,2 %.",
            "old": null,
            "new": "-12.2 %",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Duration",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Duração registado como 13 weeks.",
            "old": null,
            "new": "13 weeks",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Participants",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Participantes registado como 280.",
            "old": null,
            "new": "280",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Pivotal trial",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Ensaio pivotal registado como VENTURE-Oral.",
            "old": null,
            "new": "VENTURE-Oral",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "VK2735 (oral) · Class",
            "entity": "vk2735-oral",
            "summary": "VK2735 (oral): Classe registado como Dual GLP-1 / GIP agonist.",
            "old": null,
            "new": "Dual GLP-1 / GIP agonist",
            "citation": {
                "title": "VK2735 (oral) — Viking Therapeutics",
                "url": "https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html",
                "publisher": "VK2735 (oral)",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Placebo-adjusted",
            "entity": "survodutide",
            "summary": "Survodutide: Ajustado ao placebo registado como -7,6 pp.",
            "old": null,
            "new": "-7.6 pp",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Placebo arm",
            "entity": "survodutide",
            "summary": "Survodutide: Braço de placebo registado como -5,4 %.",
            "old": null,
            "new": "-5.4 %",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Weight change",
            "entity": "survodutide",
            "summary": "Survodutide: Variação de peso registado como -13,0 %.",
            "old": null,
            "new": "-13.0 %",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Duration",
            "entity": "survodutide",
            "summary": "Survodutide: Duração registado como 76 weeks.",
            "old": null,
            "new": "76 weeks",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Participants",
            "entity": "survodutide",
            "summary": "Survodutide: Participantes registado como 725.",
            "old": null,
            "new": "725",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Pivotal trial",
            "entity": "survodutide",
            "summary": "Survodutide: Ensaio pivotal registado como SYNCHRONIZE-1.",
            "old": null,
            "new": "SYNCHRONIZE-1",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Survodutide · Class",
            "entity": "survodutide",
            "summary": "Survodutide: Classe registado como Dual glucagon + GLP-1 agonist.",
            "old": null,
            "new": "Dual glucagon + GLP-1 agonist",
            "citation": {
                "title": "Survodutide — Boehringer Ingelheim / Zealand",
                "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
                "publisher": "Survodutide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Placebo-adjusted",
            "entity": "maritide",
            "summary": "MariTide: Ajustado ao placebo registado como -13,7 pp.",
            "old": null,
            "new": "-13.7 pp",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Placebo arm",
            "entity": "maritide",
            "summary": "MariTide: Braço de placebo registado como -2,5 %.",
            "old": null,
            "new": "-2.5 %",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Weight change",
            "entity": "maritide",
            "summary": "MariTide: Variação de peso registado como -16,2 %.",
            "old": null,
            "new": "-16.2 %",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Duration",
            "entity": "maritide",
            "summary": "MariTide: Duração registado como 52 weeks.",
            "old": null,
            "new": "52 weeks",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Participants",
            "entity": "maritide",
            "summary": "MariTide: Participantes registado como 592.",
            "old": null,
            "new": "592",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Pivotal trial",
            "entity": "maritide",
            "summary": "MariTide: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "MariTide · Class",
            "entity": "maritide",
            "summary": "MariTide: Classe registado como GIP receptor antagonist conjugated to a GLP-1 agonist.",
            "old": null,
            "new": "GIP receptor antagonist conjugated to a GLP-1 agonist",
            "citation": {
                "title": "MariTide — Amgen",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
                "publisher": "MariTide",
                "kind": "journal",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Placebo-adjusted",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Placebo arm",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Weight change",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Variação de peso registado como -16,3 %.",
            "old": null,
            "new": "-16.3 %",
            "citation": {
                "title": "Aleniglipron — Structure Therapeutics",
                "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                "publisher": "Aleniglipron",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Duration",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Duração registado como 44 weeks.",
            "old": null,
            "new": "44 weeks",
            "citation": {
                "title": "Aleniglipron — Structure Therapeutics",
                "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                "publisher": "Aleniglipron",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Participants",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Participantes registado como 85.",
            "old": null,
            "new": "85",
            "citation": {
                "title": "Aleniglipron — Structure Therapeutics",
                "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                "publisher": "Aleniglipron",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Pivotal trial",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Ensaio pivotal registado como ACCESS II.",
            "old": null,
            "new": "ACCESS II",
            "citation": {
                "title": "Aleniglipron — Structure Therapeutics",
                "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                "publisher": "Aleniglipron",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Aleniglipron · Class",
            "entity": "aleniglipron",
            "summary": "Aleniglipron: Classe registado como Oral small-molecule GLP-1 agonist.",
            "old": null,
            "new": "Oral small-molecule GLP-1 agonist",
            "citation": {
                "title": "Aleniglipron — Structure Therapeutics",
                "url": "https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-phase-2",
                "publisher": "Aleniglipron",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Placebo-adjusted",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Placebo arm",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Weight change",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Variação de peso registado como -22,1 %.",
            "old": null,
            "new": "-22.1 %",
            "citation": {
                "title": "Bimagrumab + semaglutide — Eli Lilly",
                "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                "publisher": "Bimagrumab + semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Duration",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Duração registado como 72 weeks.",
            "old": null,
            "new": "72 weeks",
            "citation": {
                "title": "Bimagrumab + semaglutide — Eli Lilly",
                "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                "publisher": "Bimagrumab + semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Participants",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Participantes registado como 507.",
            "old": null,
            "new": "507",
            "citation": {
                "title": "Bimagrumab + semaglutide — Eli Lilly",
                "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                "publisher": "Bimagrumab + semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Pivotal trial",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Ensaio pivotal registado como BELIEVE.",
            "old": null,
            "new": "BELIEVE",
            "citation": {
                "title": "Bimagrumab + semaglutide — Eli Lilly",
                "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                "publisher": "Bimagrumab + semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Bimagrumab + semaglutide · Class",
            "entity": "bimagrumab-semaglutide",
            "summary": "Bimagrumab + semaglutide: Classe registado como Anti-activin receptor antibody, muscle-sparing, combined with a GLP-1.",
            "old": null,
            "new": "Anti-activin receptor antibody, muscle-sparing, combined with a GLP-1",
            "citation": {
                "title": "Bimagrumab + semaglutide — Eli Lilly",
                "url": "https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass",
                "publisher": "Bimagrumab + semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Placebo-adjusted",
            "entity": "amycretin",
            "summary": "Amycretin: Ajustado ao placebo registado como -24,0 pp.",
            "old": null,
            "new": "-24.0 pp",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Placebo arm",
            "entity": "amycretin",
            "summary": "Amycretin: Braço de placebo registado como 2,0 %.",
            "old": null,
            "new": "2.0 %",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Weight change",
            "entity": "amycretin",
            "summary": "Amycretin: Variação de peso registado como -22,0 %.",
            "old": null,
            "new": "-22.0 %",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Duration",
            "entity": "amycretin",
            "summary": "Amycretin: Duração registado como 36 weeks.",
            "old": null,
            "new": "36 weeks",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Participants",
            "entity": "amycretin",
            "summary": "Amycretin: Participantes registado como 125.",
            "old": null,
            "new": "125",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Pivotal trial",
            "entity": "amycretin",
            "summary": "Amycretin: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Amycretin · Class",
            "entity": "amycretin",
            "summary": "Amycretin: Classe registado como Single molecule acting on GLP-1 and amylin receptors.",
            "old": null,
            "new": "Single molecule acting on GLP-1 and amylin receptors",
            "citation": {
                "title": "Amycretin — Novo Nordisk",
                "url": "https://www.biospace.com/press-releases/novo-nordisk-to-advance-subcutaneous-and-oral-amycretin-for-weight-management-into-phase-3-clinical-development",
                "publisher": "Amycretin",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Placebo-adjusted",
            "entity": "cagrisema",
            "summary": "CagriSema: Ajustado ao placebo registado como -17,4 pp.",
            "old": null,
            "new": "-17.4 pp",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Placebo arm",
            "entity": "cagrisema",
            "summary": "CagriSema: Braço de placebo registado como -3,0 %.",
            "old": null,
            "new": "-3.0 %",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Weight change",
            "entity": "cagrisema",
            "summary": "CagriSema: Variação de peso registado como -20,4 %.",
            "old": null,
            "new": "-20.4 %",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Duration",
            "entity": "cagrisema",
            "summary": "CagriSema: Duração registado como 68 weeks.",
            "old": null,
            "new": "68 weeks",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Participants",
            "entity": "cagrisema",
            "summary": "CagriSema: Participantes registado como 3 417.",
            "old": null,
            "new": "3 417",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Pivotal trial",
            "entity": "cagrisema",
            "summary": "CagriSema: Ensaio pivotal registado como REDEFINE 1.",
            "old": null,
            "new": "REDEFINE 1",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "CagriSema · Class",
            "entity": "cagrisema",
            "summary": "CagriSema: Classe registado como Amylin analogue + GLP-1 agonist.",
            "old": null,
            "new": "Amylin analogue + GLP-1 agonist",
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Placebo-adjusted",
            "entity": "retatrutide",
            "summary": "Retatrutide: Ajustado ao placebo registado como -26,1 pp.",
            "old": null,
            "new": "-26.1 pp",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Placebo arm",
            "entity": "retatrutide",
            "summary": "Retatrutide: Braço de placebo registado como -2,2 %.",
            "old": null,
            "new": "-2.2 %",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Weight change",
            "entity": "retatrutide",
            "summary": "Retatrutide: Variação de peso registado como -28,3 %.",
            "old": null,
            "new": "-28.3 %",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Duration",
            "entity": "retatrutide",
            "summary": "Retatrutide: Duração registado como 80 weeks.",
            "old": null,
            "new": "80 weeks",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Participants",
            "entity": "retatrutide",
            "summary": "Retatrutide: Participantes registado como 2 339.",
            "old": null,
            "new": "2 339",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Pivotal trial",
            "entity": "retatrutide",
            "summary": "Retatrutide: Ensaio pivotal registado como TRIUMPH-1.",
            "old": null,
            "new": "TRIUMPH-1",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Retatrutide · Class",
            "entity": "retatrutide",
            "summary": "Retatrutide: Classe registado como Triple GLP-1 / GIP / glucagon agonist.",
            "old": null,
            "new": "Triple GLP-1 / GIP / glucagon agonist",
            "citation": {
                "title": "Retatrutide — Eli Lilly",
                "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
                "publisher": "Retatrutide",
                "kind": "press",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · TGA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · Canada",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · PMDA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · ANVISA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · MHRA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da MHRA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · EMA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da EMA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · FDA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da FDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Duration",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Duração registado como 48 weeks.",
            "old": null,
            "new": "48 weeks",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Participants",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Pivotal trial",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Ensaio pivotal registado como SLIMMER.",
            "old": null,
            "new": "SLIMMER",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Placebo-adjusted",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Ajustado ao placebo registado como -15,1 pp.",
            "old": null,
            "new": "-15.1 pp",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Placebo arm",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Braço de placebo registado como -0,3 %.",
            "old": null,
            "new": "-0.3 %",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Weight change",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Variação de peso registado como -15,4 %.",
            "old": null,
            "new": "-15.4 %",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Stopped for side effects",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Dose",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Dose registado como 2.4 mg weekly.",
            "old": null,
            "new": "2.4 mg weekly",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Route",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Via de administração registado como Injection, weekly.",
            "old": null,
            "new": "Injection, weekly",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Class",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Classe registado como cAMP-biased GLP-1 receptor agonist.",
            "old": null,
            "new": "cAMP-biased GLP-1 receptor agonist",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Ecnoglutide · Brand",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: Marca registado como Ecnoglutide (brand not disclosed).",
            "old": null,
            "new": "Ecnoglutide (brand not disclosed)",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · TGA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · Canada",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · PMDA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · ANVISA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · MHRA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da MHRA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · EMA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da EMA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · FDA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da FDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Duration",
            "entity": "mazdutide",
            "summary": "Mazdutide: Duração registado como 48 weeks.",
            "old": null,
            "new": "48 weeks",
            "citation": {
                "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                "publisher": "Mazdutide: First Approval, Drugs 2025",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Participants",
            "entity": "mazdutide",
            "summary": "Mazdutide: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Pivotal trial",
            "entity": "mazdutide",
            "summary": "Mazdutide: Ensaio pivotal registado como GLORY-1.",
            "old": null,
            "new": "GLORY-1",
            "citation": {
                "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                "publisher": "Mazdutide: First Approval, Drugs 2025",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Placebo-adjusted",
            "entity": "mazdutide",
            "summary": "Mazdutide: Ajustado ao placebo registado como -14,3 pp.",
            "old": null,
            "new": "-14.3 pp",
            "citation": {
                "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                "publisher": "Mazdutide: First Approval, Drugs 2025",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Placebo arm",
            "entity": "mazdutide",
            "summary": "Mazdutide: Braço de placebo registado como -0,5 %.",
            "old": null,
            "new": "-0.5 %",
            "citation": {
                "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                "publisher": "Mazdutide: First Approval, Drugs 2025",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Weight change",
            "entity": "mazdutide",
            "summary": "Mazdutide: Variação de peso registado como -14,8 %.",
            "old": null,
            "new": "-14.8 %",
            "citation": {
                "title": "Mazdutide: First Approval, Drugs 2025 — PubMed 41028652",
                "url": "https://pubmed.ncbi.nlm.nih.gov/41028652/",
                "publisher": "Mazdutide: First Approval, Drugs 2025",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Stopped for side effects",
            "entity": "mazdutide",
            "summary": "Mazdutide: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Dose",
            "entity": "mazdutide",
            "summary": "Mazdutide: Dose registado como 4 mg or 6 mg weekly.",
            "old": null,
            "new": "4 mg or 6 mg weekly",
            "citation": {
                "title": "Innovent — NMPA approval for chronic weight management",
                "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                "publisher": "Innovent",
                "kind": "press",
                "primary": false,
                "published_on": "2025-06-27",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Route",
            "entity": "mazdutide",
            "summary": "Mazdutide: Via de administração registado como Injection, weekly.",
            "old": null,
            "new": "Injection, weekly",
            "citation": {
                "title": "Innovent — NMPA approval for chronic weight management",
                "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                "publisher": "Innovent",
                "kind": "press",
                "primary": false,
                "published_on": "2025-06-27",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Class",
            "entity": "mazdutide",
            "summary": "Mazdutide: Classe registado como Dual glucagon + GLP-1 receptor agonist.",
            "old": null,
            "new": "Dual glucagon + GLP-1 receptor agonist",
            "citation": {
                "title": "Innovent — NMPA approval for chronic weight management",
                "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                "publisher": "Innovent",
                "kind": "press",
                "primary": false,
                "published_on": "2025-06-27",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Mazdutide · Brand",
            "entity": "mazdutide",
            "summary": "Mazdutide: Marca registado como Xin Er Mei (信尔美).",
            "old": null,
            "new": "Xin Er Mei (信尔美)",
            "citation": {
                "title": "Innovent — NMPA approval for chronic weight management",
                "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                "publisher": "Innovent",
                "kind": "press",
                "primary": false,
                "published_on": "2025-06-27",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · TGA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · Canada",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · NMPA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · PMDA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da PMDA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · ANVISA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · MHRA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da MHRA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Duration",
            "entity": "metreleptin",
            "summary": "Metreleptin: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Participants",
            "entity": "metreleptin",
            "summary": "Metreleptin: Participantes registado como 107.",
            "old": null,
            "new": "107",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Pivotal trial",
            "entity": "metreleptin",
            "summary": "Metreleptin: Ensaio pivotal registado como NIH open-label cohort.",
            "old": null,
            "new": "NIH open-label cohort",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Placebo-adjusted",
            "entity": "metreleptin",
            "summary": "Metreleptin: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Placebo arm",
            "entity": "metreleptin",
            "summary": "Metreleptin: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Weight change",
            "entity": "metreleptin",
            "summary": "Metreleptin: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Stopped for side effects",
            "entity": "metreleptin",
            "summary": "Metreleptin: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Dose",
            "entity": "metreleptin",
            "summary": "Metreleptin: Dose registado como Up to 10 mg daily.",
            "old": null,
            "new": "Up to 10 mg daily",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Route",
            "entity": "metreleptin",
            "summary": "Metreleptin: Via de administração registado como Injection, daily.",
            "old": null,
            "new": "Injection, daily",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Class",
            "entity": "metreleptin",
            "summary": "Metreleptin: Classe registado como Recombinant leptin analogue.",
            "old": null,
            "new": "Recombinant leptin analogue",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Metreleptin · Brand",
            "entity": "metreleptin",
            "summary": "Metreleptin: Marca registado como Myalept (US) / Myalepta (EU).",
            "old": null,
            "new": "Myalept (US) / Myalepta (EU)",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · TGA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · Canada",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · NMPA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · PMDA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · ANVISA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · MHRA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da MHRA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Duration",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Duração registado como 52 weeks.",
            "old": null,
            "new": "52 weeks",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Participants",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Participantes registado como 142.",
            "old": null,
            "new": "142",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Pivotal trial",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Ensaio pivotal registado como TRANSCEND.",
            "old": null,
            "new": "TRANSCEND",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Placebo-adjusted",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Ajustado ao placebo registado como -18,4 pp.",
            "old": null,
            "new": "-18.4 pp",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Placebo arm",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Braço de placebo registado como 2,6 %.",
            "old": null,
            "new": "2.6 %",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Weight change",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Variação de peso registado como -15,8 %.",
            "old": null,
            "new": "-15.8 %",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Stopped for side effects",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Dose",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Dose registado como Titrated by age and weight, up to 3 mg daily.",
            "old": null,
            "new": "Titrated by age and weight, up to 3 mg daily",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Route",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Via de administração registado como Injection, daily.",
            "old": null,
            "new": "Injection, daily",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Class",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Classe registado como MC4R agonist.",
            "old": null,
            "new": "MC4R agonist",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Setmelanotide · Brand",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: Marca registado como Imcivree.",
            "old": null,
            "new": "Imcivree",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · TGA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da TGA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · Canada",
            "entity": "phentermine",
            "summary": "Phentermine: posição da Canada registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · NMPA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · PMDA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · ANVISA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · MHRA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da MHRA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · EMA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da EMA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Duration",
            "entity": "phentermine",
            "summary": "Phentermine: Duração registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Participants",
            "entity": "phentermine",
            "summary": "Phentermine: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Pivotal trial",
            "entity": "phentermine",
            "summary": "Phentermine: Ensaio pivotal registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Placebo-adjusted",
            "entity": "phentermine",
            "summary": "Phentermine: Ajustado ao placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Placebo arm",
            "entity": "phentermine",
            "summary": "Phentermine: Braço de placebo registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Weight change",
            "entity": "phentermine",
            "summary": "Phentermine: Variação de peso registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Stopped for side effects",
            "entity": "phentermine",
            "summary": "Phentermine: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Dose",
            "entity": "phentermine",
            "summary": "Phentermine: Dose registado como 37.5 mg daily.",
            "old": null,
            "new": "37.5 mg daily",
            "citation": {
                "title": "FDA — Adipex-P label, rev. 01/2012",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2012-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Route",
            "entity": "phentermine",
            "summary": "Phentermine: Via de administração registado como Tablet, daily.",
            "old": null,
            "new": "Tablet, daily",
            "citation": {
                "title": "FDA — Adipex-P label, rev. 01/2012",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2012-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Class",
            "entity": "phentermine",
            "summary": "Phentermine: Classe registado como Sympathomimetic amine anorectic.",
            "old": null,
            "new": "Sympathomimetic amine anorectic",
            "citation": {
                "title": "FDA — Adipex-P label, rev. 01/2012",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2012-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine · Brand",
            "entity": "phentermine",
            "summary": "Phentermine: Marca registado como Adipex-P, Lomaira, Duromine.",
            "old": null,
            "new": "Adipex-P, Lomaira, Duromine",
            "citation": {
                "title": "FDA — Adipex-P label, rev. 01/2012",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2012-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · Canada",
            "entity": "orlistat",
            "summary": "Orlistat: posição da Canada registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · NMPA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da NMPA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · ANVISA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da ANVISA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Duration",
            "entity": "orlistat",
            "summary": "Orlistat: Duração registado como 208 weeks.",
            "old": null,
            "new": "208 weeks",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Participants",
            "entity": "orlistat",
            "summary": "Orlistat: Participantes registado como 3 305.",
            "old": null,
            "new": "3 305",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Pivotal trial",
            "entity": "orlistat",
            "summary": "Orlistat: Ensaio pivotal registado como XENDOS.",
            "old": null,
            "new": "XENDOS",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Placebo-adjusted",
            "entity": "orlistat",
            "summary": "Orlistat: Ajustado ao placebo registado como -2,4 pp.",
            "old": null,
            "new": "-2.4 pp",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Placebo arm",
            "entity": "orlistat",
            "summary": "Orlistat: Braço de placebo registado como -2,8 %.",
            "old": null,
            "new": "-2.8 %",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Weight change",
            "entity": "orlistat",
            "summary": "Orlistat: Variação de peso registado como -5,2 %.",
            "old": null,
            "new": "-5.2 %",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Stopped for side effects",
            "entity": "orlistat",
            "summary": "Orlistat: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Dose",
            "entity": "orlistat",
            "summary": "Orlistat: Dose registado como 120 mg with each fat-containing meal; 60 mg over the counter.",
            "old": null,
            "new": "120 mg with each fat-containing meal; 60 mg over the counter",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Route",
            "entity": "orlistat",
            "summary": "Orlistat: Via de administração registado como Capsule, three times daily.",
            "old": null,
            "new": "Capsule, three times daily",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Class",
            "entity": "orlistat",
            "summary": "Orlistat: Classe registado como Gastrointestinal lipase inhibitor.",
            "old": null,
            "new": "Gastrointestinal lipase inhibitor",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orlistat · Brand",
            "entity": "orlistat",
            "summary": "Orlistat: Marca registado como Xenical (Rx) / alli (OTC).",
            "old": null,
            "new": "Xenical (Rx) / alli (OTC)",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Canada",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da Canada registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · NMPA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · PMDA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · ANVISA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Duration",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Duração registado como 56 weeks.",
            "old": null,
            "new": "56 weeks",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Participants",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Participantes registado como 1 074.",
            "old": null,
            "new": "1 074",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Pivotal trial",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Ensaio pivotal registado como COR-I.",
            "old": null,
            "new": "COR-I",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Placebo-adjusted",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Ajustado ao placebo registado como -4,1 pp.",
            "old": null,
            "new": "-4.1 pp",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Placebo arm",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Braço de placebo registado como -1,3 %.",
            "old": null,
            "new": "-1.3 %",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Weight change",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Variação de peso registado como -5,4 %.",
            "old": null,
            "new": "-5.4 %",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Stopped for side effects",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Abandono por efeitos adversos registado como 24% vs 12% placebo — by far the highest of any approved agent.",
            "old": null,
            "new": "24% vs 12% placebo — by far the highest of any approved agent",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Dose",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Dose registado como 32 mg / 360 mg daily.",
            "old": null,
            "new": "32 mg / 360 mg daily",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Route",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Via de administração registado como Tablet, twice daily.",
            "old": null,
            "new": "Tablet, twice daily",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Class",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Classe registado como Opioid antagonist + aminoketone antidepressant.",
            "old": null,
            "new": "Opioid antagonist + aminoketone antidepressant",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · Brand",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: Marca registado como Contrave (US) / Mysimba (EU).",
            "old": null,
            "new": "Contrave (US) / Mysimba (EU)",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · TGA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Canada",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · NMPA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · PMDA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · ANVISA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · MHRA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da MHRA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Duration",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Duração registado como 56 weeks.",
            "old": null,
            "new": "56 weeks",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Participants",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Participantes registado como 2 487.",
            "old": null,
            "new": "2 487",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Pivotal trial",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Ensaio pivotal registado como CONQUER.",
            "old": null,
            "new": "CONQUER",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Placebo-adjusted",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Ajustado ao placebo registado como -8,6 pp.",
            "old": null,
            "new": "-8.6 pp",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Placebo arm",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Braço de placebo registado como -1,2 %.",
            "old": null,
            "new": "-1.2 %",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Weight change",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Variação de peso registado como -9,8 %.",
            "old": null,
            "new": "-9.8 %",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Stopped for side effects",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Abandono por efeitos adversos registado como Label reports only all-cause withdrawal of 31–40%, which is not comparable to other drugs' figures.",
            "old": null,
            "new": "Label reports only all-cause withdrawal of 31–40%, which is not comparable to other drugs' figures",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Dose",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Dose registado como 7.5/46 mg or 15/92 mg daily.",
            "old": null,
            "new": "7.5/46 mg or 15/92 mg daily",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Route",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Via de administração registado como Tablet, daily.",
            "old": null,
            "new": "Tablet, daily",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Class",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Classe registado como Sympathomimetic + anticonvulsant combination.",
            "old": null,
            "new": "Sympathomimetic + anticonvulsant combination",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Phentermine / topiramate ER · Brand",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: Marca registado como Qsymia.",
            "old": null,
            "new": "Qsymia",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Canada",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da Canada registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · NMPA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · PMDA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · ANVISA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da ANVISA registada como aprovado.",
            "old": null,
            "new": "approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Duration",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Duração registado como 56 weeks.",
            "old": null,
            "new": "56 weeks",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Participants",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Participantes registado como 3 731.",
            "old": null,
            "new": "3 731",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Pivotal trial",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Ensaio pivotal registado como SCALE Obesity and Prediabetes.",
            "old": null,
            "new": "SCALE Obesity and Prediabetes",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Placebo-adjusted",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Ajustado ao placebo registado como -5,4 pp.",
            "old": null,
            "new": "-5.4 pp",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Placebo arm",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Braço de placebo registado como -2,6 %.",
            "old": null,
            "new": "-2.6 %",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Weight change",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Variação de peso registado como -8,0 %.",
            "old": null,
            "new": "-8.0 %",
            "citation": {
                "title": "SCALE, NEJM 2015;373:11",
                "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892",
                "publisher": "nejm.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2015-07-02",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Stopped for side effects",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Dose",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Dose registado como 3.0 mg daily.",
            "old": null,
            "new": "3.0 mg daily",
            "citation": {
                "title": "EMA — Saxenda EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Route",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Via de administração registado como Injection, daily.",
            "old": null,
            "new": "Injection, daily",
            "citation": {
                "title": "EMA — Saxenda EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Class",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Classe registado como GLP-1 receptor agonist.",
            "old": null,
            "new": "GLP-1 receptor agonist",
            "citation": {
                "title": "EMA — Saxenda EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · Brand",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: Marca registado como Saxenda + generics.",
            "old": null,
            "new": "Saxenda + generics",
            "citation": {
                "title": "EMA — Saxenda EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · TGA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · Canada",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · NMPA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · PMDA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · ANVISA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · MHRA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da MHRA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · EMA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da EMA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Duration",
            "entity": "orforglipron",
            "summary": "Orforglipron: Duração registado como 72 weeks.",
            "old": null,
            "new": "72 weeks",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Participants",
            "entity": "orforglipron",
            "summary": "Orforglipron: Participantes registado como 3 127.",
            "old": null,
            "new": "3 127",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Pivotal trial",
            "entity": "orforglipron",
            "summary": "Orforglipron: Ensaio pivotal registado como ATTAIN-1.",
            "old": null,
            "new": "ATTAIN-1",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Placebo-adjusted",
            "entity": "orforglipron",
            "summary": "Orforglipron: Ajustado ao placebo registado como -9,0 pp.",
            "old": null,
            "new": "-9.0 pp",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Placebo arm",
            "entity": "orforglipron",
            "summary": "Orforglipron: Braço de placebo registado como -2,1 %.",
            "old": null,
            "new": "-2.1 %",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Weight change",
            "entity": "orforglipron",
            "summary": "Orforglipron: Variação de peso registado como -11,1 %.",
            "old": null,
            "new": "-11.1 %",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Stopped for side effects",
            "entity": "orforglipron",
            "summary": "Orforglipron: Abandono por efeitos adversos registado como 8% vs 3% placebo — the highest of the GLP-1 agents.",
            "old": null,
            "new": "8% vs 3% placebo — the highest of the GLP-1 agents",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Dose",
            "entity": "orforglipron",
            "summary": "Orforglipron: Dose registado como Up to 17.2 mg daily, no food or water restrictions.",
            "old": null,
            "new": "Up to 17.2 mg daily, no food or water restrictions",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Route",
            "entity": "orforglipron",
            "summary": "Orforglipron: Via de administração registado como Tablet, daily.",
            "old": null,
            "new": "Tablet, daily",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Class",
            "entity": "orforglipron",
            "summary": "Orforglipron: Classe registado como Small-molecule (non-peptide) GLP-1 receptor agonist.",
            "old": null,
            "new": "Small-molecule (non-peptide) GLP-1 receptor agonist",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Orforglipron · Brand",
            "entity": "orforglipron",
            "summary": "Orforglipron: Marca registado como Foundayo.",
            "old": null,
            "new": "Foundayo",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Duration",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Duração registado como 72 weeks.",
            "old": null,
            "new": "72 weeks",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Participants",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Participantes registado como 2 539.",
            "old": null,
            "new": "2 539",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Pivotal trial",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Ensaio pivotal registado como SURMOUNT-1.",
            "old": null,
            "new": "SURMOUNT-1",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Placebo-adjusted",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Ajustado ao placebo registado como -17,8 pp.",
            "old": null,
            "new": "-17.8 pp",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Placebo arm",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Braço de placebo registado como -3,1 %.",
            "old": null,
            "new": "-3.1 %",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Weight change",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Variação de peso registado como -20,9 %.",
            "old": null,
            "new": "-20.9 %",
            "citation": {
                "title": "SURMOUNT-1 — PubMed 35658024",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
                "publisher": "SURMOUNT-1",
                "kind": "journal",
                "primary": true,
                "published_on": "2022-06-04",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Stopped for side effects",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Abandono por efeitos adversos registado como 4.8–6.7% vs 3.4% placebo.",
            "old": null,
            "new": "4.8–6.7% vs 3.4% placebo",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Dose",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Dose registado como 5, 10 or 15 mg weekly.",
            "old": null,
            "new": "5, 10 or 15 mg weekly",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Route",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Via de administração registado como Injection, weekly.",
            "old": null,
            "new": "Injection, weekly",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Class",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Classe registado como Dual GIP + GLP-1 receptor agonist.",
            "old": null,
            "new": "Dual GIP + GLP-1 receptor agonist",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Tirzepatide · Brand",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: Marca registado como Zepbound (US) / Mounjaro.",
            "old": null,
            "new": "Zepbound (US) / Mounjaro",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · TGA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Canada",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · NMPA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · PMDA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · ANVISA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da ANVISA registada como em avaliação.",
            "old": null,
            "new": "under review",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Duration",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Duração registado como 64 weeks.",
            "old": null,
            "new": "64 weeks",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Participants",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Participantes registado como 307.",
            "old": null,
            "new": "307",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Pivotal trial",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Ensaio pivotal registado como OASIS 4.",
            "old": null,
            "new": "OASIS 4",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Placebo-adjusted",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Ajustado ao placebo registado como -12,0 pp.",
            "old": null,
            "new": "-12.0 pp",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Placebo arm",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Braço de placebo registado como -2,0 %.",
            "old": null,
            "new": "-2.0 %",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Weight change",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Variação de peso registado como -14,0 %.",
            "old": null,
            "new": "-14.0 %",
            "citation": {
                "title": "OASIS 4 — PubMed 40934115",
                "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/",
                "publisher": "OASIS 4",
                "kind": "journal",
                "primary": true,
                "published_on": "2025-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Stopped for side effects",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Abandono por efeitos adversos registado como 7% vs 6% placebo.",
            "old": null,
            "new": "7% vs 6% placebo",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Dose",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Dose registado como 25 mg daily, on an empty stomach with ≤120 ml water, then nothing for 30 minutes.",
            "old": null,
            "new": "25 mg daily, on an empty stomach with ≤120 ml water, then nothing for 30 minutes",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Route",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Via de administração registado como Tablet, daily.",
            "old": null,
            "new": "Tablet, daily",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Class",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Classe registado como GLP-1 receptor agonist.",
            "old": null,
            "new": "GLP-1 receptor agonist",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · Brand",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: Marca registado como Wegovy tablets.",
            "old": null,
            "new": "Wegovy tablets",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · TGA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da TGA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Canada",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da Canada registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · NMPA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da NMPA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · PMDA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da PMDA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · ANVISA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da ANVISA registada como não aprovado.",
            "old": null,
            "new": "not approved",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Duration",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Duração registado como 72 weeks.",
            "old": null,
            "new": "72 weeks",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Participants",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Participantes registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Pivotal trial",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Ensaio pivotal registado como STEP UP.",
            "old": null,
            "new": "STEP UP",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Placebo-adjusted",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Ajustado ao placebo registado como -15,7 pp.",
            "old": null,
            "new": "-15.7 pp",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Placebo arm",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Braço de placebo registado como -3,8 %.",
            "old": null,
            "new": "-3.8 %",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Weight change",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Variação de peso registado como -19,5 %.",
            "old": null,
            "new": "-19.5 %",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Stopped for side effects",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Abandono por efeitos adversos registado como —.",
            "old": null,
            "new": "—",
            "citation": null
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Dose",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Dose registado como 7.2 mg weekly, escalated from 2.4 mg.",
            "old": null,
            "new": "7.2 mg weekly, escalated from 2.4 mg",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Route",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Via de administração registado como Injection, weekly.",
            "old": null,
            "new": "Injection, weekly",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Class",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Classe registado como GLP-1 receptor agonist.",
            "old": null,
            "new": "GLP-1 receptor agonist",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · Brand",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: Marca registado como Wegovy HD.",
            "old": null,
            "new": "Wegovy HD",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Duration",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Duração registado como 68 weeks.",
            "old": null,
            "new": "68 weeks",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Participants",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Participantes registado como 1 961.",
            "old": null,
            "new": "1 961",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Pivotal trial",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Ensaio pivotal registado como STEP 1.",
            "old": null,
            "new": "STEP 1",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Placebo-adjusted",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Ajustado ao placebo registado como -12,5 pp.",
            "old": null,
            "new": "-12.5 pp",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Placebo arm",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Braço de placebo registado como -2,4 %.",
            "old": null,
            "new": "-2.4 %",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Weight change",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Variação de peso registado como -14,9 %.",
            "old": null,
            "new": "-14.9 %",
            "citation": {
                "title": "SELECT trial summary, NEJM 2023;389:2221",
                "url": "https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select",
                "publisher": "acc.org",
                "kind": "journal",
                "primary": true,
                "published_on": "2023-11-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Stopped for side effects",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Abandono por efeitos adversos registado como 6.8% vs 3.2% placebo.",
            "old": null,
            "new": "6.8% vs 3.2% placebo",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Dose",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Dose registado como 2.4 mg weekly after a 16-week escalation.",
            "old": null,
            "new": "2.4 mg weekly after a 16-week escalation",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Route",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Via de administração registado como Injection, weekly.",
            "old": null,
            "new": "Injection, weekly",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Class",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Classe registado como GLP-1 receptor agonist.",
            "old": null,
            "new": "GLP-1 receptor agonist",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-21",
            "kind": "spec",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Brand",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: Marca registado como Wegovy.",
            "old": null,
            "new": "Wegovy",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-20",
            "kind": "new",
            "generated": false,
            "subject": "This page",
            "entity": null,
            "summary": "Primeira publicação. Catorze medicamentos aprovados, nove compostos em investigação, seis fracassos e dez péptidos não aprovados, cada um verificado contra fontes primárias dos reguladores em vez da cobertura de imprensa.",
            "old": null,
            "new": null,
            "citation": {
                "title": "This page — 2026-08-20",
                "url": "https://www.accessdata.fda.gov/scripts/cder/daf/",
                "publisher": "This page",
                "kind": "regulator",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-20",
            "kind": "correction",
            "generated": false,
            "subject": "Mazdutide · Ecnoglutide · Imcivree · Sevmia",
            "entity": null,
            "summary": "Quatro datas despromovidas depois de uma passagem de verificação independente. As datas de aprovação chinesas do mazdutido e do ecnoglutido são datas de anúncio do promotor, não confirmadas pelo regulador — a base de dados da NMPA não é acessível por meios automáticos. A extensão europeia do Imcivree passa a mostrar a data do parecer do CHMP, 27 de março de 2026, porque a data da decisão da Comissão não é publicada. E o Sevmia passa a ser descrito como o primeiro genérico de semaglutido indicado para o controlo do peso, e não como o primeiro genérico de semaglutido no Canadá, que não é.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Mazdutide · Ecnoglutide · Imcivree · Sevmia — 2026-08-20",
                "url": "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107181",
                "publisher": "Mazdutide · Ecnoglutide · Imcivree · Sevmia",
                "kind": "regulator",
                "primary": true,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-20",
            "kind": "correction",
            "generated": false,
            "subject": "Semaglutide 7.2 mg (Wegovy HD)",
            "entity": "semaglutide-72",
            "summary": "CORREÇÃO, no mesmo dia da publicação. Registámos primeiro que o braço de placebo do STEP UP nunca tinha sido publicado, e não mostrámos qualquer valor ajustado ao placebo. Estava errado: os resultados tabelados completos sempre estiveram publicados no ClinicalTrials.gov, e dão −19,5% contra um braço de placebo de −3,8% — uma diferença ajustada ao placebo de 15,7 pontos. O erro veio de nos apoiarmos na cobertura de imprensa e no artigo pago da revista, em vez do registo. A linha passa a levar os valores do registo, e a nota explica por que razão o título de −20,7% da empresa é diferente.",
            "old": "—",
            "new": "-15.7 pp",
            "citation": {
                "title": "ClinicalTrials.gov NCT05646706 — posted results including the placebo arm",
                "url": "https://clinicaltrials.gov/study/NCT05646706",
                "publisher": "ClinicalTrials.gov NCT05646706",
                "kind": "journal",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-08-17",
            "kind": "status",
            "generated": false,
            "subject": "Semaglutide",
            "entity": null,
            "summary": "A ANVISA aprovou o primeiro genérico de semaglutido fabricado no Brasil (EMS, com a Germed no mesmo dia). O Brasil torna-se o segundo país com um genérico, depois do Canadá.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Semaglutide — 2026-08-17",
                "url": "https://www.poder360.com.br/poder-saude/anvisa-aprova-1o-generico-de-semaglutida-fabricado-no-brasil/",
                "publisher": "Semaglutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-07-23",
            "kind": "status",
            "generated": false,
            "subject": "Retatrutide",
            "entity": "retatrutide",
            "summary": "A Lilly confirmou que a submissão escorregou para 2027. Registado como atraso e não como fracasso — mas significa que o composto mais eficaz desta página está a pelo menos dois anos de qualquer farmácia.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Retatrutide — 2026-07-23",
                "url": "https://www.cnbc.com/2026/07/23/eli-lilly-will-file-for-approval-of-retatrutide-obesity-drug-in-2027.html",
                "publisher": "Retatrutide",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-07-23",
            "kind": "correction",
            "generated": false,
            "subject": "Unapproved peptides",
            "entity": null,
            "summary": "Um painel consultivo da FDA votou por margem estreita a favor de permitir a manipulação de seis péptidos — BPC-157, KPV e TB-500 por 8 votos contra 6 com uma abstenção, e MOTS-c por 7 contra 5 com duas. O emideltide foi rejeitado. Isto vai ser amplamente noticiado como legalização. Não é: os votos não são vinculativos, a regulamentação ainda não começou, o ciclo comparável anterior demorou mais de dois anos, e a própria nota informativa da FDA dizia que os estudos eram demasiado curtos e demasiado pequenos para estabelecer segurança ou eficácia.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Unapproved peptides — 2026-07-23",
                "url": "https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding",
                "publisher": "Unapproved peptides",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-07-15",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · EMA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da EMA registada como aprovado · 15 jul 2026.",
            "old": null,
            "new": "approved · 15 Jul 2026",
            "citation": null
        },
        {
            "happened_on": "2026-07-15",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · EMA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da EMA registada como aprovado · 15 jul 2026.",
            "old": null,
            "new": "approved · 15 Jul 2026",
            "citation": null
        },
        {
            "happened_on": "2026-06-29",
            "kind": "status",
            "generated": false,
            "subject": "Semaglutide",
            "entity": null,
            "summary": "A Health Canada autorizou o Sevmia, da Apotex, o primeiro genérico de semaglutido indicado para o controlo crónico do peso. A imprensa especializada atribui a entrada antecipada a uma taxa de manutenção de patente que caducou; o próprio comunicado da Health Canada não o diz, pelo que registamos isso como reportado e não como estabelecido.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Health Canada — first generic semaglutide approved",
                "url": "https://www.canada.ca/en/health-canada/news/2026/06/canada-approves-first-generic-semaglutide-for-weight-loss.html",
                "publisher": "Health Canada",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-06-29",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-06-11",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · MHRA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da MHRA registada como aprovado · 11 jun 2026.",
            "old": null,
            "new": "approved · 11 Jun 2026",
            "citation": {
                "title": "Pharmaceutical Journal — MHRA approves oral semaglutide",
                "url": "https://pharmaceutical-journal.com/article/news/mhra-approves-semaglutide-oral-tablets-for-weight-loss",
                "publisher": "Pharmaceutical Journal",
                "kind": "trade",
                "primary": false,
                "published_on": "2026-06-11",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-04-30",
            "kind": "status",
            "generated": false,
            "subject": "Compounded GLP-1s",
            "entity": null,
            "summary": "A FDA propôs excluir permanentemente o semaglutido, o tirzepatido e o liraglutido da lista de substâncias 503B, o que fecharia de vez a manipulação a granel dos três.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Compounded GLP-1s — 2026-04-30",
                "url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s",
                "publisher": "Compounded GLP-1s",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-04-01",
            "kind": "new",
            "generated": false,
            "subject": "Orforglipron",
            "entity": "orforglipron",
            "summary": "Aprovado pela FDA como Foundayo — o primeiro GLP-1 oral de pequena molécula. Avaliado em 50 dias ao abrigo do programa National Priority Voucher. Acrescentado à lista; o argumento de que «não existe um comprimido» para justificar a compra no mercado paralelo fica materialmente mais fraco.",
            "old": null,
            "new": null,
            "citation": {
                "title": "FDA — first NME approved under the National Priority Voucher programme",
                "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-04-01",
            "kind": "approval",
            "generated": true,
            "subject": "Orforglipron · FDA",
            "entity": "orforglipron",
            "summary": "Orforglipron: posição da FDA registada como aprovado · abril 2026.",
            "old": null,
            "new": "approved · April 2026",
            "citation": {
                "title": "FDA — Foundayo label, rev. 04/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-04-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-03-27",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · EMA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da EMA registada como aprovado · 27 mar 2026.",
            "old": null,
            "new": "approved · 27 Mar 2026",
            "citation": {
                "title": "EMA — Imcivree EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-03-19",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · FDA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da FDA registada como aprovado · 19 mar 2026.",
            "old": null,
            "new": "approved · 19 Mar 2026",
            "citation": null
        },
        {
            "happened_on": "2026-03-06",
            "kind": "new",
            "generated": false,
            "subject": "Ecnoglutide",
            "entity": "ecnoglutide",
            "summary": "Aprovado pela NMPA da China. Acrescentado com a ressalva de que o seu ensaio pivotal não tem dimensão de amostra publicada nem publicação revista por pares.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-03-06",
            "kind": "approval",
            "generated": true,
            "subject": "Ecnoglutide · NMPA",
            "entity": "ecnoglutide",
            "summary": "Ecnoglutide: posição da NMPA registada como aprovado · 6 mar 2026.",
            "old": null,
            "new": "approved · 6 Mar 2026",
            "citation": {
                "title": "Sciwind — NMPA approval of ecnoglutide",
                "url": "https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html",
                "publisher": "Sciwind",
                "kind": "press",
                "primary": false,
                "published_on": "2026-03-06",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-02-23",
            "kind": "correction",
            "generated": false,
            "subject": "CagriSema",
            "entity": "cagrisema",
            "summary": "O REDEFINE 4 falhou o endpoint primário: não se demonstrou que o CagriSema fosse não inferior ao tirzepatido em comparação direta. Registado com destaque porque a cobertura para o consumidor sobre o CagriSema tem omitido este facto quase sempre.",
            "old": null,
            "new": null,
            "citation": {
                "title": "CagriSema — Novo Nordisk",
                "url": "https://www.patientcareonline.com/view/cagrisema-achieves-23-weight-loss-but-misses-noninferiority-vs-tirzepatide-in-redefine-4",
                "publisher": "CagriSema",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2026-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 7.2 mg · MHRA",
            "entity": "semaglutide-72",
            "summary": "Semaglutide 7.2 mg: posição da MHRA registada como aprovado · janeiro 2026.",
            "old": null,
            "new": "approved · January 2026",
            "citation": null
        },
        {
            "happened_on": "2025-12-22",
            "kind": "new",
            "generated": false,
            "subject": "Oral semaglutide 25 mg",
            "entity": null,
            "summary": "A FDA aprovou o primeiro GLP-1 oral para controlo do peso. Atenção à diferença de estimando: a empresa cita 16,6% e o endpoint primário do NEJM é cerca de 14%.",
            "old": null,
            "new": null,
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2025-12-22",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 25 mg, oral · FDA",
            "entity": "oral-semaglutide",
            "summary": "Semaglutide 25 mg, oral: posição da FDA registada como aprovado · 22 dez 2025.",
            "old": null,
            "new": "approved · 22 Dec 2025",
            "citation": {
                "title": "FDA — Wegovy tablets label, rev. 12/2025",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2025-12-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2025-12-01",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · TGA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da TGA registada como retirado · dezembro 2025.",
            "old": null,
            "new": "withdrawn · December 2025",
            "citation": null
        },
        {
            "happened_on": "2025-06-27",
            "kind": "approval",
            "generated": true,
            "subject": "Mazdutide · NMPA",
            "entity": "mazdutide",
            "summary": "Mazdutide: posição da NMPA registada como aprovado · 27 jun 2025.",
            "old": null,
            "new": "approved · 27 Jun 2025",
            "citation": {
                "title": "Innovent — NMPA approval for chronic weight management",
                "url": "https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html",
                "publisher": "Innovent",
                "kind": "press",
                "primary": false,
                "published_on": "2025-06-27",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2025-06-09",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · ANVISA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da ANVISA registada como aprovado · 9 jun 2025.",
            "old": null,
            "new": "approved · 9 Jun 2025",
            "citation": {
                "title": "Agência Brasil — ANVISA approves Mounjaro for weight loss",
                "url": "https://agenciabrasil.ebc.com.br/saude/noticia/2025-06/anvisa-aprova-uso-do-medicamento-mounjaro-para-perda-de-peso",
                "publisher": "Agência Brasil",
                "kind": "trade",
                "primary": false,
                "published_on": "2025-06-09",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2025-05-13",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · Canada",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da Canada registada como aprovado · 13 mai 2025.",
            "old": null,
            "new": "approved · 13 May 2025",
            "citation": null
        },
        {
            "happened_on": "2025-04-14",
            "kind": "death",
            "generated": false,
            "subject": "Danuglipron",
            "entity": "danuglipron",
            "summary": "A Pfizer descontinuou o seu GLP-1 oral depois de uma possível lesão hepática induzida pelo medicamento — o segundo GLP-1 oral da empresa morto por um sinal hepático.",
            "old": null,
            "new": null,
            "citation": {
                "title": "Danuglipron",
                "url": "https://www.biopharmadive.com/news/pfizer-discontinue-obesity-pill-danuglipron/745235/",
                "publisher": "biopharmadive.com",
                "kind": "trade",
                "primary": false,
                "published_on": null,
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2024-12-01",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · PMDA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da PMDA registada como aprovado · dezembro 2024.",
            "old": null,
            "new": "approved · December 2024",
            "citation": null
        },
        {
            "happened_on": "2024-07-19",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · NMPA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da NMPA registada como aprovado · 19 jul 2024.",
            "old": null,
            "new": "approved · 19 Jul 2024",
            "citation": null
        },
        {
            "happened_on": "2024-06-01",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · NMPA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da NMPA registada como aprovado · junho 2024.",
            "old": null,
            "new": "approved · June 2024",
            "citation": null
        },
        {
            "happened_on": "2024-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · TGA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da TGA registada como aprovado · janeiro 2024.",
            "old": null,
            "new": "approved · January 2024",
            "citation": null
        },
        {
            "happened_on": "2023-11-08",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · FDA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da FDA registada como aprovado · 8 nov 2023.",
            "old": null,
            "new": "approved · 8 Nov 2023",
            "citation": {
                "title": "FDA — Zepbound label, rev. 01/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2023-11-01",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · MHRA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da MHRA registada como aprovado · novembro 2023.",
            "old": null,
            "new": "approved · November 2023",
            "citation": null
        },
        {
            "happened_on": "2023-11-01",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · MHRA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da MHRA registada como aprovado · novembro 2023.",
            "old": null,
            "new": "approved · November 2023",
            "citation": null
        },
        {
            "happened_on": "2023-03-10",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · PMDA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da PMDA registada como aprovado · 10 mar 2023.",
            "old": null,
            "new": "approved · 10 Mar 2023",
            "citation": null
        },
        {
            "happened_on": "2023-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · PMDA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da PMDA registada como aprovado · janeiro 2023.",
            "old": null,
            "new": "approved · January 2023",
            "citation": null
        },
        {
            "happened_on": "2023-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · TGA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da TGA registada como aprovado · janeiro 2023.",
            "old": null,
            "new": "approved · January 2023",
            "citation": null
        },
        {
            "happened_on": "2023-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · ANVISA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da ANVISA registada como aprovado · janeiro 2023.",
            "old": null,
            "new": "approved · January 2023",
            "citation": null
        },
        {
            "happened_on": "2022-09-15",
            "kind": "approval",
            "generated": true,
            "subject": "Tirzepatide · EMA",
            "entity": "tirzepatide",
            "summary": "Tirzepatide: posição da EMA registada como aprovado · 15 set 2022.",
            "old": null,
            "new": "approved · 15 Sep 2022",
            "citation": null
        },
        {
            "happened_on": "2022-01-06",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · EMA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da EMA registada como aprovado · 6 jan 2022.",
            "old": null,
            "new": "approved · 6 Jan 2022",
            "citation": {
                "title": "EMA — Wegovy EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2021-11-25",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · Canada",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da Canada registada como aprovado · 25 nov 2021.",
            "old": null,
            "new": "approved · 25 Nov 2021",
            "citation": {
                "title": "Health Canada — first generic semaglutide approved",
                "url": "https://www.canada.ca/en/health-canada/news/2026/06/canada-approves-first-generic-semaglutide-for-weight-loss.html",
                "publisher": "Health Canada",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-06-29",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2021-06-04",
            "kind": "approval",
            "generated": true,
            "subject": "Semaglutide 2.4 mg · FDA",
            "entity": "semaglutide-24",
            "summary": "Semaglutide 2.4 mg: posição da FDA registada como aprovado · 4 jun 2021.",
            "old": null,
            "new": "approved · 4 Jun 2021",
            "citation": {
                "title": "FDA — Wegovy label, rev. 03/2026",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2020-11-25",
            "kind": "approval",
            "generated": true,
            "subject": "Setmelanotide · FDA",
            "entity": "setmelanotide",
            "summary": "Setmelanotide: posição da FDA registada como aprovado · 25 nov 2020.",
            "old": null,
            "new": "approved · 25 Nov 2020",
            "citation": null
        },
        {
            "happened_on": "2019-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · TGA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da TGA registada como aprovado · janeiro 2019.",
            "old": null,
            "new": "approved · January 2019",
            "citation": null
        },
        {
            "happened_on": "2018-07-30",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · EMA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da EMA registada como aprovado · 30 jul 2018.",
            "old": null,
            "new": "approved · 30 Jul 2018",
            "citation": {
                "title": "EMA — Myalepta EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2015-03-26",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · MHRA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da MHRA registada como aprovado · 26 mar 2015.",
            "old": null,
            "new": "approved · 26 Mar 2015",
            "citation": null
        },
        {
            "happened_on": "2015-03-26",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · EMA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da EMA registada como aprovado · 26 mar 2015.",
            "old": null,
            "new": "approved · 26 Mar 2015",
            "citation": {
                "title": "EMA — Mysimba EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2015-03-23",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · MHRA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da MHRA registada como aprovado · 23 mar 2015.",
            "old": null,
            "new": "approved · 23 Mar 2015",
            "citation": null
        },
        {
            "happened_on": "2015-03-23",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · EMA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da EMA registada como aprovado · 23 mar 2015.",
            "old": null,
            "new": "approved · 23 Mar 2015",
            "citation": {
                "title": "EMA — Saxenda EPAR",
                "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2026-08-20",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2014-12-23",
            "kind": "approval",
            "generated": true,
            "subject": "Liraglutide 3.0 mg · FDA",
            "entity": "liraglutide",
            "summary": "Liraglutide 3.0 mg: posição da FDA registada como aprovado · 23 dez 2014.",
            "old": null,
            "new": "approved · 23 Dec 2014",
            "citation": null
        },
        {
            "happened_on": "2014-09-10",
            "kind": "approval",
            "generated": true,
            "subject": "Naltrexone / bupropion ER · FDA",
            "entity": "contrave",
            "summary": "Naltrexone / bupropion ER: posição da FDA registada como aprovado · 10 set 2014.",
            "old": null,
            "new": "approved · 10 Sep 2014",
            "citation": {
                "title": "FDA — Contrave label, rev. 03/2021",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2021-03-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2014-02-24",
            "kind": "approval",
            "generated": true,
            "subject": "Metreleptin · FDA",
            "entity": "metreleptin",
            "summary": "Metreleptin: posição da FDA registada como aprovado · 24 fev 2014.",
            "old": null,
            "new": "approved · 24 Feb 2014",
            "citation": {
                "title": "FDA — Myalept label",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2014-02-24",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2013-02-21",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · EMA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da EMA registada como recusado · 21 fev 2013.",
            "old": null,
            "new": "refused · 21 Feb 2013",
            "citation": {
                "title": "EMA — Qsiva refusal question-and-answer document",
                "url": "https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_en.pdf",
                "publisher": "EMA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2013-02-21",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2012-07-17",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine / topiramate ER · FDA",
            "entity": "qsymia",
            "summary": "Phentermine / topiramate ER: posição da FDA registada como aprovado · 17 jul 2012.",
            "old": null,
            "new": "approved · 17 Jul 2012",
            "citation": {
                "title": "FDA — Qsymia label, rev. 09/2024",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022580s026lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2024-09-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "2000-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · TGA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da TGA registada como aprovado · janeiro 2000.",
            "old": null,
            "new": "approved · January 2000",
            "citation": null
        },
        {
            "happened_on": "1999-04-26",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · FDA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da FDA registada como aprovado · 26 abr 1999.",
            "old": null,
            "new": "approved · 26 Apr 1999",
            "citation": {
                "title": "FDA — Xenical label, rev. 11/2022",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2022-11-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        },
        {
            "happened_on": "1998-07-29",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · MHRA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da MHRA registada como aprovado · 29 jul 1998.",
            "old": null,
            "new": "approved · 29 Jul 1998",
            "citation": null
        },
        {
            "happened_on": "1998-07-29",
            "kind": "approval",
            "generated": true,
            "subject": "Orlistat · EMA",
            "entity": "orlistat",
            "summary": "Orlistat: posição da EMA registada como aprovado · 29 jul 1998.",
            "old": null,
            "new": "approved · 29 Jul 1998",
            "citation": null
        },
        {
            "happened_on": "1959-01-01",
            "kind": "approval",
            "generated": true,
            "subject": "Phentermine · FDA",
            "entity": "phentermine",
            "summary": "Phentermine: posição da FDA registada como aprovado · janeiro 1959.",
            "old": null,
            "new": "approved · January 1959",
            "citation": {
                "title": "FDA — Adipex-P label, rev. 01/2012",
                "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf",
                "publisher": "FDA",
                "kind": "regulator",
                "primary": true,
                "published_on": "2012-01-01",
                "retrieved_at": "2026-08-20T00:00:00+00:00"
            }
        }
    ]
}